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Abstract
Early identification of neuroanatomical changes deviating from the normal age-related atrophy
pattern has the potential to improve clinical outcomes through early treatment or prophylaxis.
Especially the pathological cascade of Alzheimer’s disease (AD), the most common form of
dementia, is widely linked to precocious and/or accelerated (brain) aging.
This work presents a novel magnetic resonance imaging (MRI)-based biomarker that indi-
cates discrepancies in individual brain aging and even predicts prospective cognitive decline. By
employing automatic preprocessing of structural MR images as well as high-dimensional pattern
recognition methods, the BrainAGE approach uses the distribution of normal brain-aging pat-
terns to estimate the brain age of a given new subject. The di↵erence between the estimated and
the chronological age is termed the brain age gap estimation (BrainAGE) score, with positive
values indicating the degree of acceleration in cerebral atrophy, which is considered a risk factor
for AD.
The BrainAGE approach proved to be a reliable, scanner-independent, and e cient method
for brain age estimation in healthy subjects, yielding a correlation of r = 0.92 between the
chronological and the estimated brain age. Moreover, with significantly increased BrainAGE
scores in AD patients, in subjects who converted to AD during follow up, and even in subjects
with diabetes mellitus type 2 (T2DM), the BrainAGE framework demonstrated its potential
to indicate accelerated brain aging. Additionally, increased BrainAGE scores were profoundly
associated with disease severity and prospective worsening of cognitive functions.
Most clinically valuable, the BrainAGE outperformed all cognitive scales, hippocampus
volume, and state-of-the-art biomarkers derived from cerebrospinal fluid (CSF) in predicting
prospective conversion to AD. Furthermore, each additional year in the BrainAGE score was
associated with a nearly 10% greater risk of developing AD within the next 36 months.
In conclusion, the BrainAGE approach showed promising results on an individual level,
contributing to an early detection of abnormal brain aging, and providing important prognostic
information. Its fast and fully automated nature facilitates the integration into the clinical
workflow, thus qualifying as a tool for screening as well as for monitoring treatment options.
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Zusammenfassung
Die fru¨hzeitige Identifikation neuro-anatomischer Vera¨nderungen, die vom normalen Atrophie-
Muster abweichen, kann klinische Prognosen durch eine fru¨hzeitige Behandlung oder Prophylaxe
verbessern. Insbesondere die Alzheimer Demenz (AD), die ha¨ufigste Art der Demenz, scheint
mit einer vorzeitigen und / oder beschleunigten (Gehirn-) Alterung zusammen zu ha¨ngen.
Diese Arbeit pra¨sentiert einen neuartigen Magnetresonanztomographie(MRI)-gestu¨tzten Bio-
marker, der auf Abweichungen in der individuellen Gehirnalterung hinweist und kognitiven Ver-
fall voraussagt. Mittels automatisierter Vorverarbeitung von strukturellen MRI-Daten sowie
hoch-dimensionaler Mustererkennungsmethoden modelliert der BrainAGE -Ansatz den Verlauf
von normaler Gehirnalterung. Anschliessend kann das Gehirnalter eines neuen Probanden ge-
scha¨tzt werden. Die Di↵erenz zwischen dem gescha¨tzten und dem chronologischen Alter wird
“brain age gap estimation (BrainAGE)” genannt, wobei positive Werte den Grad der Beschleu-
nigung in der Gehirnatrophie anzeigen und somit auf ein erho¨htes Risiko fu¨r AD hinweisen.
Mit einer Korrelation von r = 0.92 zwischen dem chronologischen und dem gescha¨tzten
Gehirnalter in einer Gruppe gesunder Probanden hat sich der BrainAGE -Ansatz als eine zu-
verla¨ssige, Scanner-unabha¨ngige und e ziente Methode fu¨r die Scha¨tzung des Gehirnalters er-
wiesen. Mit signifikant erho¨hten BrainAGE -Werten in AD-Patienten, in Probanden, die wa¨hrend
des follow-ups zu AD konvertieren, und sogar in Patienten mit Diabetes mellitus Typ 2 (T2DM),
hat die BrainAGE -Methode ausserdem sein Potenzial demonstriert, beschleunigte Gehirnal-
terung zu identifizieren. Weiterhin gehen erho¨hte BrainAGE -Werte mit dem Schweregrad der
AD-Symptome und mit der zuku¨nftigen Verschlechterung kognitiver Funktionen einher.
Im Vergleich zu verschiedenen kognitiven Tests, zum Hippocampus-Volumen und zu den
state-of-the-art Biomarkern aus der cerebrospinalen Flu¨ssigkeit (CSF) hat die BrainAGE -Metho-
de eine zuku¨nftiger Konvertierung zu AD am genauesten vorhergesagt. Jedes zusa¨tzliche Jahr
in den BrainAGE -Werten war mit einem ca. 10% gro¨sseren Risiko verbunden, innerhalb der
na¨chsten 36 Monate zu AD zu konvertieren.
Somit stellt die BrainAGE -Methode einen vielversprechende Ansatz dar, abweichende Muster
in der individuellen Gehirnalterung fru¨hzeitig festzustellen und wichtige prognostische Informa-
tionen zu liefern. Da die BrainAGE -Methode schnell und vo¨llig automatisiert arbeitet, ko¨nnte sie
zuku¨nftig beispielsweise als Screeninginstrument oder zur Bewertung von Behandlungserfolgen
in den klinischen Arbeitsablauf integriert werden.
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Chapter 1
General Introduction
“If the brain were so simple we could understand it, we would be so simple we couldn’t.” (Lyall Watson)
Understanding the brain, and in particular understanding the processes occurring during
healthy as well as abnormal brain aging, is one of the intriguing questions of mankind. This
chapter outlines the general context in which the BrainAGE approach was developed and im-
plemented. First, neuroanatomical insights into normal brain aging are briefly reviewed. Then,
diverse variables are described that influence neurodegenerative processes and therefore add to
the variability seen in age-related brain changes. Some of these variables are supposed to lead to
accelerated brain atrophy that shows the pattern of faster brain aging. Finally, research findings
are summarized suggesting that processes of accelerated brain aging will make the brain more
vulnerable to neurodegenerative diseases, especially Alzheimer’s disease (AD).
1.1 Age-related changes of the human brain structure
Postmortem and histological studies of the human brain have discovered a wide range of age-
related changes in brain structure (Raz and Rodrigue, 2006). Amongst others, reduced brain
weight and volume as well as sulcal expansion were revealed on a coarse level (Kemper, 1994;
Pakkenberg and Gundersen, 1997; Skullerud, 1985). Research at cellular levels also detected
several atrophy processes, including loss of neocortical neurons over the life span by about 10%
in both sexes (Pakkenberg and Gundersen, 1997), decrease in the number of neurons in the
hippocampal formation (Simic´ et al., 1997) and the cerebellum (Ellis, 1920), decline of the
white matter (WM) structure, with a primary loss of thinner fibers and a relative preservation
of the thicker ones (Marner et al., 2003; Meier-Ruge et al., 1992), reduction in synaptic density
(Morrison and Hof, 1997), dea↵erentation within the hippocampus (Bertoni-Freddari et al.,
2002), and significant loss of dendritic spines (Jacobs et al., 1997). Taken together, although
some age-related changes are a↵ecting the brain globally, most findings suggest a rather region-
and layer-specific reduction (Uylings and de Brabander, 2002).
But it was only after the advent of magnetic resonance imaging (MRI) that neuroimaging
studies contributed to a better understanding of brain aging – especially when it comes to
longitudinal studies, which were obviously not possible to conduct before. In addition, with the
5
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availability of automated computational methods for analyzing MRI data, such as voxel-based
morphometry (VBM; Ashburner and Friston, 2000), it has become feasible to quantify and
visualize structural brain changes in vivo (May, 2011).
Healthy brain aging has been found to follow highly coordinated and sequenced patterns.
Pfe↵erbaum et al. (1994) showed that gray matter (GM) volume increases from birth until
the age of four and thereafter decreases continuously until subjects reach their 70s, while WM
volume increases steadily until around the age of 20 when it plateaus. Cerebrospinal fluid (CSF)
was found to exhibit a complementary pattern, remaining constant until about 20 years of age
and increasing steadily thereafter (Pfe↵erbaum et al., 1994).
The pattern of linear GM decline and CSF increase being predominant in normal aging is
also supported by a more recent, fully automated VBM study (Good et al., 2001). Further-
more, local areas of accelerated GM decline and microstructural changes in WM were reported,
suggesting a heterogeneous and complex pattern of atrophy across the adult life span (Good
et al., 2001). Evidence for more region-specific and non-linear patterns of neurodegenerative
age-related changes in GM volume were provided by cross-sectional morphometric analyses (for
detailed reviews see Raz, 2000; Raz et al., 2004; Raz and Rodrigue, 2006) as well as longitudinal
studies (Resnick et al., 2003). These results support the hypothesis of normal age-related GM
decline being inversely related to the phylogenetic origin of each respective region, with younger
structures being the last to mature as well as being more vulnerable to neurodegeneration (Ter-
ribilli et al., 2011; Toga et al., 2006). Recent magnetic resonance spectroscopy (MRS) studies
provided evidence of specific age-related di↵erences in neural viability and integrity, thus sug-
gesting that the age-associated shrinkage in selected GM regions might reflect a decrease in the
size and/or number of neurons (Kadota et al., 2001; Raz and Rodrigue, 2006).
Although WM volume was observed to remain relatively stable across adulthood, age ap-
pears to be the strongest predictor of di↵erences in its microstructure (Kemper, 1994; Raz and
Rodrigue, 2006), especially in white matter hyperintensities (WMH). WMHs were found to
be caused by diverse neuropathological changes, including myelin pallor, atrophy of neuropil,
damage in the subependymal ventricular linging (De Leeuw et al., 2001), subclinical ischemia
(Pantoni et al., 1996), reduction in cerebral perfusion and greater vulnerability of the border
zones (Brant-Zawadzki et al., 1987). Like in GM, the frontal regions appear to be a↵ected first
by WHM burden (Fazekas et al., 2005; Raz et al., 2003a,b,c). Furthermore, Artero et al. (2004)
suggested a pattern of progression of WM lesions into temporal and occipital areas across time.
In summary, neuroanatomical aging is characterized by a widespread but well-ordered as
well as region-specific brain tissue loss and CSF expansion.
1.2 Variability in brain aging
Though neuroanatomical aging is characterized by a widespread but rather specific pattern of
alterations, multiple factors a↵ect and modify those individual trajectories. For instance, several
markers of poor health and/or an inappropriate lifestyle seem to be associated with the risk of
cognitive decline, greater brain atrophy, and even dementia, including the metabolic syndrome,
hypertension, diabetes, nicotine and alcohol abuse, elevated serum total homocysteine (tHcy),
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and lower levels of vitamin B12 (Chen et al., 2009; Clarke et al., 1998; Clarke, 2006; Clarke
et al., 2007; Debette et al., 2010; Ellinson et al., 2004; Enzinger et al., 2005; Fitzpatrick et al.,
2009; Middleton and Ya↵e, 2009; Oulhaj et al., 2010; Solfrizzi et al., 2011; Steele et al., 2007;
Zylberstein et al., 2011). Furthermore, combination of risk factors was found to further boost
the risk (Luchsinger et al., 2005).
In contrast, a healthy and well-balanced lifestyle, including physical activity, normal body
weight, smoking cessation, a Mediterranean diet, especially a high intake of unsaturated fatty
acids, and moderate alcohol intake, was shown to lower the risk of cognitive decline and dementia
(Erickson et al., 2010; Fe´art et al., 2010; Frisardi et al., 2010; Gu et al., 2010; Luchsinger and
Gustafson, 2009; Nepal et al., 2010; Peters et al., 2008; Scarmeas et al., 2009; Solfrizzi et al.,
2008; Xu et al., 2009).
In particular, hypertension appears to significantly boost the e↵ects of aging on a wide range
of neuroanatomical changes (De Leeuw et al., 2001; den Heijer et al., 2005; Carmelli et al.,
1999; Goldstein et al., 2002; Raz et al., 2003a,b,c; Raz and Rodrigue, 2006; Salerno et al.,
1992; Schmidt et al., 2003; Strassburger et al., 1997), even if treated (Raz et al., 2003a,b,c; van
Swieten et al., 1991). Furthermore, hypertension was suggested to accelerate the age-related
atrophy of the hippocampus (Du et al., 2006; Raz et al., 2005). Additionally, cardiovascular risk
factors significantly accelerate age-related changes in GM, especially in the hippocampus and in
posterior regions (Whalley et al., 2003; Williams et al., 2002). Hence, the hippocampus seems
to be eminently vulnerable to those risk factors (Raz and Rodrigue, 2006).
Although age appears to be the strongest predictor of WMH, cerebrovascular risk factors
were found to be additionally related to increased WMH burden (Raz and Rodrigue, 2006),
including hypertension, ischemic attacks, atherosclerosis, decreased cortical blood vessel disease,
and small vessel disease (Brown et al., 2002; De Leeuw et al., 2001; Kidwell et al., 2001; Markus
et al., 2005; Moody et al., 2004; Pico et al., 2002). Moreover, the progression of WM lesions
into temporal and occipital areas was observed to be associated with the presence of distinct
clinical symptoms, including hypertension, depression, and poor cognitive functioning (Artero
et al., 2004).
Furthermore, Apolipoprotein E (APOE) genotype was identified to be associated with faster
cognitive decline in late life (Alexander et al., 2012; Donix et al., 2012; Harris and Deary, 2011;
Van Gerven et al., 2012) as well as with the risk of developing cognitive impairment (Deary
et al., 2002; Heise et al., 2011) and even AD (Rocchi et al., 2003; Trachtenberg et al., 2012).
Especially the APOE "4 allele is linked to the modification of cognitive functioning (Cosentino
et al., 2008; Deary et al., 2002; Wishart et al., 2006) and GM reduction in healthy subjects
(Bookheimer et al., 2000) as well as AD patients (Filippini et al., 2009).
1.3 Associations of brain structures with cognitive functions
To date, the associations between brain structure and cognitive functioning in normal aging are
rather puzzling. Due to the lack of broad and well-controlled longitudinal studies combining
neuroimaging with cognitive assessments, neither the true magnitude nor even the directions of
age-related structure-function associations have been reliably assessed yet (Raz and Rodrigue,
CHAPTER 1. GENERAL INTRODUCTION 8
2006).
Nevertheless, preliminary studies suggest better executive functioning to be associated with
larger prefrontal cortices (Gunning-Dixon and Raz, 2003; Raz et al., 1998) as well as less frontal
WMH (Gunning-Dixon and Raz, 2003). Enhanced skill acquisition performance was suggested
to be associated with larger volumes of striatal structures, prefrontal cortex, and cerebellum
(Kennedy and Raz, 2005; Raz, 2000; Woodru↵-Pak et al., 2001). Longitudinal shrinkage of the
entorhinal cortex (EC) was found to be related to reduced memory performance in healthy
adults (Du et al., 2003; Rodrigue and Raz, 2004) and even future memory declines (de Leon
et al., 2001). Decline in executive functioning was observed to be associated with longitudinal
WMH increase (Cook et al., 2004).
On the other hand, several studies suggest that the degree of brain pathology does not
directly relate to clinical manifestation of that damage (Fotenos et al., 2008; Katzman et al.,
1989; Snowdon, 1997, 2003; Stern, 2006; Tyas et al., 2007). Higher premorbid IQ, education,
occupational attainment, and participation in leisure activities were found to be associated
with reduced risk of developing AD (Albert and Teresi, 1999; Alexander et al., 1997; Evans
et al., 1993; Mortel et al., 1995; Stern et al., 1994, 1995; Stern, 2006; Richards and Sacker,
2003). Thus, the model of cognitive reserve (CR) was developed (Stern, 2002, 2003, 2006),
suggesting that “the brain actively attempts to cope with brain damage by using preexisting
cognitive processing approaches or by enlisting compensatory approaches. Individuals with more
CR would be more successful at coping with the same amount of brain damage.” (Stern, 2006).
More specifically, Stern suggested two di↵erent – not mutually exclusive – mechanisms that could
provide sustainment against structural brain damage before showing cognitive decline (Stern
et al., 2005; Stern, 2006). Neural reserve refers to more e cient brain networks already existing
in healthy individuals. Hence, these networks are less susceptible to disruption. Additionally,
in neural compensation the disruption of preexisting networks is compensated by the use of
alternate brain networks and cognitive strategies. Consequently, individuals who show the same
level of cognitive decline or clinical severity may have divergent levels of underlying brain damage,
with more advanced AD pathology being associated with higher levels of CR (Fotenos et al.,
2008; Stern, 2006).
1.4 Accelerated brain atrophy in neurodegenerative diseases
With the growing number of studies that have investigated both normal and abnormal brain
changes with age, most major neuropsychiatric and neurodegenerative disorders are now thought
to arise due to deviations from normal structural brain aging, including schizophrenia (Giedd
et al., 2009; Meda et al., 2008; Paus et al., 2008), depression (Paus et al., 2008), and AD
(Ashburner et al., 2003).
Especially AD, the most common form of dementia (Brookmeyer et al., 2007), is widely
assumed to be preceded by accelerated aging (for a controversial view see Nelson et al., 2011;
Ohnishi et al., 2001). Recently, atrophic regions detected in AD patients were found to largely
overlap with those regions showing a normal age-related decline in healthy control subjects
(Dukart et al., 2011). The current understanding of the AD disease course suggests that manifold
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Figure 1.1: Dynamic biomarkers of the Alzheimer’s pathological cascade. A  is identified by
CSF A 42 or PET amlyloid imaging. Tau-mediated neuronal injury and dysfunction is identified by CSF
tau or FDG-PET. Brain structure is measured using structural MRI. [Figure and legend from Jack et al.
2010.]
pathological changes accumulate over many years in the first place years or decades before the
onset of clinical symptoms; and secondly, cognitive decline occurrs gradually, with dementia
representing the final stage of the pathological cascade (Figure 1.1; Frisoni et al., 2010; Jack
et al., 2010). These pathological changes include premature changes in gene expression (Cao
et al., 2010; Saetre et al., 2011), accelerated age-associated changes of the default mode network
(Jones et al., 2011), and most obviously, abnormal changes in brain structures at the stage of
mild cognitive impairment(MCI; Driscoll et al., 2009; Spulber et al., 2010; Wang et al., 2009)
and even in normal-functioning individuals (Clark et al., 2012; Davatzikos et al., 2009).
Particularly, the process of A -plaque accumulation begins at least 5 – 10 years (Buchhave
et al., 2012) or even up to two decades before probable manifestation of clinical symptoms
and conversion to AD (Jack et al., 2009), but on its own is not su cient to cause dementia
(Aizenstein et al., 2008; Jack et al., 2010; Peskind et al., 2006; Price and Morris, 1999; Price
et al., 2009; Savva et al., 2009). Especially low concentrations of CSF A 42, associated with
the formation of A  plaques in the brain, were found to correlate with the clinical diagnosis
of AD (Clark et al., 2003; Strozyk et al., 2003), but not with rates of brain atrophy (Josephs
et al., 2008). At some point in the AD disease course accelerated neurodegeneration takes place,
which is manifesting as atrophy, neuron loss, loss of synapses, and gliosis (Jack et al., 2010).
Neurodegeneration, which precedes accelerated cognitive decline (Jack et al., 2010) as well as
cognitive impairment (Buchhave et al., 2012; Shaw et al., 2009), is indicated by increasing CSF
tau levels. However, increased phosphorylated tau (P-Tau) and total tau (T-Tau) is not specific
for AD but seems to indicate neuronal injury and neurodegeneration in general (Jack et al., 2010;
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Hesse et al., 2001; Schoonenboom et al., 2012). Nevertheless, CSF tau was found to correlate with
clinical disease severity, with increased levels being associated with greater cognitive impairment
(Jack et al., 2010; Shaw et al., 2009). Although brain atrophy revealed by MRI in general is
likewise not specific for AD, MRI was found to retain the closest relationship with cognitive
decline (Jack et al., 2010; Vemuri et al., 2009a,b) suggesting a crucial role for structural MRI
in predicting future conversion to AD (Jack et al., 2010; Frisoni et al., 2010). Importantly, the
individual disease course is suggested to be modulated by diverse factors such as risk-associated
and protective genes (e.g., APOE), converging comorbidity, and cognitive reserve (Figure 1.2;
Ewers et al., 2011; Jack et al., 2010).
The myelin model of the human brain suggests an explanation of the anatomical processes
underlying the continuum of cognitive decline in later life leading to AD and integrates the
diverse results regarding the pathogenesis of AD (Bartzokis, 2004, 2011; Bartzokis et al., 2012;
Lu et al., 2011, 2013). It proposes that the processes of myelin development, maintenance, and
the eventual breakdown of the myelin repair process across the lifespan are underlying the unique
cognitive abilities in humans, but are also underlying the unique vulnerability to neuropsychiatric
(e.g. schizophrenia) and neurodegenerative disorders such as AD (Bartzokis, 2004, 2011). More
specifically, the model assumes regions that myelinate later in brain development, are first and
maximally a↵ected by the aging process (Bartzokis, 2004, 2011; Lu et al., 2013). Likewise, the
pattern of AD lesions was suggested to recapitulate the myelination pattern in reverse (Braak
and Braak, 1996), with the earliest maturing cortex being least vulnerable to aging and AD
(Figure 1.3; Ewers et al., 2011; Gogtay et al., 2004).
In particular, the need for myelin repair increases in older age and is most distinct in later-
myelinating regions (e.g., frontal lobe white matter, genu of the corpus callosum) due to higher
proportions of thinly-myelinated axons in these regions (Bartzokis, 2004, 2011; Lu et al., 2013;
Marner et al., 2003; Salat et al., 2005). Contrariwise, successful demyelination slows with age
(Bartzokis, 2011; Shen et al., 2008; Shields et al., 1999). Thus, as a function of genetic variability
and several other modifying factors (see section 1.2), the myelin repair processes become less
e cient and e↵ective, resulting in age-related myelin breakdown and thus in axonal transport
disruptions. As a byproduct, A  is suggested to be released and bound to the receptors, which
may increase toxicity to synapses (Bartzokis, 2011; Laure´n et al., 2009; Selkoe, 2008; Shankar
et al., 2008), surrounding myelin (Bartzokis, 2011; Muse et al., 2001), and dendrites (Bartzokis,
2011). Likewise, an increase in hyperphosphorylated tau is also proposed to represent a byprod-
uct of the myelin repair process (Bartzokis, 2011). Finally, the age-related myelin breakdown
results in an “Alzheimerization” of the human brain, including A -plaque accumulation and
increasing CSF tau levels, as well as synapse and neuron loss, leading to distinct brain lesions
(Bartzokis, 2011). Consequently, aging – and more specifically, brain aging – is associated with a
widespread and sequential pattern of tissue loss, whereas early and/or more pronounced myelin
breakdown may lead to severe pathologic manifestations of diseases such as AD.
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Figure 1.2: Modulators of biomarker temporal relationships. (A,B) Relative to a fixed age (here,
65 years), the hypothesized e↵ect of APOE "4 is to shift  -amyloid plaque deposition and the neurode-
generative cascade both to an earlier age compared with "4 non-carriers. (C) The hypothesized e↵ect
of the presence of di↵erent diseases and genes on cognition: C = cognition in the presence of comor-
bidities (e.g., Lewy bodies or vascular disease) or risk amplification genes; C+= cognition in patients
with enhanced cognitive reserve or protective genes; C0= cognition in individuals without comorbidity
or enhanced cognitive reserve. [Figure and legend from Jack et al. 2010.]
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Figure 1.3: Degenerative sequence of brain changes in AD is the reverse order of the normal
developmental sequence. In a process termed retrogenesis (e.g., by Reisberg et al., 1999), cortical
regions that mature earliest in infancy tend to degenerate last in AD. The developmental sequence
echoes the phylogenetic sequence in which structures evolved. The most heavily myelinated structures,
with least neuronal plasticity, resist AD-related neurodegeneration. Arrows denote the childhood cortical
maturation sequence (left panel; Gogtay et al., 2004) and the gray matter atrophy sequence in AD (right
panel; Thompson et al., 2003). Images are from time-lapse films compiled from cortical models in subjects
scanned longitudinally with MRI. [Figure and legend from Ewers et al. 2011.]
1.5 The BrainAGE approach
Relying upon previously acquired insights and models, accelerated and thus pathological brain
atrophy should be recognizable quite early and before the onset of cognitive decline and clinical
symptoms. Hence, identifying accelerated brain atrophy before the onset of clinical symptoms
as well as predicting the prospective cognitive decline and subsequent transition to AD will
contribute to early treatment or prophylaxis.
Assuming AD to be preceded by precocious and/or accelerated brain aging (Bartzokis, 2011;
Driscoll et al., 2009; Spulber et al., 2010), a straightforward and e cient solution is to model
healthy aging on the one hand, and to identify accelerated (thus pathological) brain atrophy
on the other. Consequently, in order to recognize faster brain atrophy, a model of healthy and
normal brain aging is needed. A straightforward and e cient solution is to model age regression
based on normal brain anatomy, such that an individual’s age can be accurately estimated from
his/her brain scan alone.
The BrainAGE approach takes into account the widespread, sequential brain tissue loss as-
sociated with aging. Based on single time-point structural MRI, the complex, multidimensional
aging patterns across the whole brain are aggregated to one single value, i.e. the estimated brain
age (Figure 1.4 A). Consequently, although using only one MRI scan per subject, the deviation
in brain atrophy from normal brain aging can be directly quantified (Figure 1.4 B).
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Figure 1.4: Depiction of the BrainAGE concept. (A) The model of healthy brain aging is trained
with the chronological age and preprocessed structural MRI data of a training sample (left, with an
exemplary illustration of the most important voxel locations that were used by the age regression model).
Subsequently, the individual brain ages of previously unseen test subjects are estimated, based on their
MRI data (picture modified from Scho¨lkopf and Smola, 2002). (B) The di↵erence between the estimated
and chronological age results in the BrainAGE score. Consequently, positive BrainAGE scores indicate
accelerated brain aging. [Figure and legend modified from Franke et al. 2012a.]
In chapter 2, the BrainAGE framework, which automatically estimates the age of healthy
subjects from their T1-weighted MRI scans, is introduced and tested. In chapter 3, the sta-
bility of individual BrainAGE scores over multiple time points and across di↵erent scanners is
examined. Furthermore, the BrainAGE framework is implemented to examine longitudinal brain
changes in cognitively healthy subjects, subjects with MCI, and AD patients. In chapter 4, the
e↵ects of type 2 diabetes mellitus (T2DM) on individual brain aging as well as its relationships
to clinically significant risk factors and functionality measures is investigated. In chapter 5, the
BrainAGE approach is implemented to predict prospective conversion to AD on an individual
subject level.
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Abstract
The early identification of brain anatomy deviating from the normal pattern of growth and atro-
phy, such as in Alzheimer’s disease (AD), has the potential to improve clinical outcomes through
early intervention. Recently, Davatzikos et al. (2009) supported the hypothesis that pathologic
atrophy in AD is an accelerated aging process, implying accelerated brain atrophy. In order to
recognize faster brain atrophy, a model of healthy brain aging is needed first. Here, we introduce
a framework for automatically and e ciently estimating the age of healthy subjects from their
T1-weighted MRI scans using a kernel method for regression. This method was tested on over
650 healthy subjects, aged 1986 years, and collected from four di↵erent scanners. Furthermore,
the influence of various parameters on estimation accuracy was analyzed. Our age estimation
framework included automatic preprocessing of the T1-weighted images, dimension reduction
via principal component analysis, training of a relevance vector machine (RVM; Tipping, 2000)
for regression, and finally estimating the age of the subjects from the test samples. The frame-
work proved to be a reliable, scanner-independent, and e cient method for age estimation in
healthy subjects, yielding a correlation of r = 0.92 between the estimated and the real age in the
test samples and a mean absolute error of 5 years. The results indicated favorable performance
of the RVM and identified the number of training samples as the critical factor for prediction
accuracy. Applying the framework to people with mild AD resulted in a mean “Brain Age Gap
Estimation” (BrainAGE) score of +10 years.
2.1 Introduction
During the normal aging process, the brain changes due to progressive (e.g., cell growth and
myelination) and regressive neuronal processes (e.g., cell death and atrophy). Brain development
and healthy aging have been found to follow a specific pattern. Using a semiautomated approach
based on a very crude geometrical method for the segmentation of the MRI data, Pfe↵erbaum
et al. (1994) showed that gray matter (GM) volume increases from birth until the age of four
and thereafter decreases continuously until subjects reach their 70s. White matter (WM) volume
increases steadily until around the age of 20 when it plateaus. Cerebrospinal fluid (CSF) exhibits
a complementary pattern, remaining constant until about 20 years of age and increasing steadily
thereafter (Pfe↵erbaum et al., 1994). A similar, but more recent study conducted a fully auto-
mated voxel-based morphometry (VBM) study with 465 normal subjects aged 17 – 79 years to
explore global and regional e↵ects of age (Good et al., 2001). The results of this cross-sectional
VBM study also suggested a linear decline in GM to be predominant in normal aging as well
as a linear increase of CSF with age. Furthermore, local areas of accelerated GM decline and
microstructural changes in WM were reported, suggesting a heterogeneous and complex pattern
of atrophy across the adult life span (Good et al., 2001). Evidence for a region-specific and
non-linear pattern of neurodegenerative age-related changes in GM volume was also provided by
cross-sectional morphometric analyses (Terribilli et al., 2011) as well as longitudinal data com-
parison (Resnick et al., 2003). These results support the hypothesis of normal age-related GM
decline being inversely related to the phylogenetic origin of each respective region, with younger
structures being the last to mature as well as being more vulnerable to neurodegeneration (see
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also Terribilli et al., 2011; Toga et al., 2006).
Diseases such as Alzheimer’s disease (AD) or schizophrenia alter brain structures in diverse
and abnormal modes (Ashburner et al., 2003; Meda et al., 2008). Developing a fully automated,
reliable, and su ciently sensitive as well as specific method for the early identification of such
pathologic brain developments even before the onset of clinical symptoms has been given great
emphasis during the last years (Ashburner, 2009; Davatzikos et al., 2009). Pathologic brain
development patterns have been explored and subsequently a variety of classification methods
have been employed to separate one or more groups of patients from healthy controls (Davatzikos
et al., 2005, 2008a,b; Fan et al., 2008a,b; Klo¨ppel et al., 2008a,b, 2009; Liu et al., 2004; Teipel
et al., 2007; Vemuri et al., 2008, 2009a,b). Most of these studies used a processing sequence
that started with segmenting and spatially normalizing MRI data, then applied some kind of
feature selection or dimensionality reduction, e.g., principal component analysis (PCA), trained
a classifier based on Support Vector Machines (SVM), and finally estimated the classification
accuracy with (jackknife) cross-validation. Typically, the sample sizes of these classification
studies were rather small, thus entailing the risk of overfitting, which could potentially produce
considerable underperformance of the trained classifier when it is applied to a completely new
sample. In order to increase sensitivity and reliability of the classification methods, Ashburner
(2009) advocated the initiation and usage of multi-scanner data sets tracking a large number of
subjects. Integrating data from di↵erent scanners in a linear SVM classification study, Klo¨ppel
et al. (2008b) reported rates for correctly classified AD patients versus healthy controls of around
90%. This suggests that kernel methods like SVM have the capability to generalize on data
obtained from various scanners.
Recently, Davatzikos et al. (2009) showed the longitudinal progression of AD-like patterns in
brain atrophy in the normal aging subjects and furthermore an accelerated AD-like atrophy in
subjects with mild cognitive impairment (MCI). These results support the hypothesis of AD be-
ing a form of accelerated aging, implying accelerated brain atrophy (Driscoll et al., 2009; Fotenos
et al., 2008; Sluimer et al., 2009; Spulber et al., 2010; Wang et al., 2009)(for a controversial view,
see Ohnishi et al., 2001). In case of schizophrenia, a similar hypothesis of the disease being a
syndrome of accelerated aging has been presented (Kirkpatrick et al., 2008). If these hypotheses
hold true in future research, accelerated and thus pathologic brain atrophy should be recogniz-
able quite early and before the onset of clinical symptoms. In order to recognize faster brain
atrophy, a model of healthy and normal brain aging is needed. A straightforward and e cient
solution is to model age regression based on normal brain anatomy such that an individual’s age
can be accurately estimated from its brain scan alone.
Until recently, only a few studies were published that perform age estimation or prediction
based on MRI scans. Lao et al. (2004) tested an SVM-based classification method by assigning
their elderly subjects into one of four age groups and reached an accuracy rate of 90%. In order to
demonstrate the performance of his algorithm for di↵eomorphic image registration, Ashburner
(2007) estimated the age of subjects based on their brain images utilizing a relevance vector
machine (RVM) for regression (Tipping, 2000, 2001). As a measure for prediction accuracy, a
root mean squared error (RMSE) of 6.5 years was reported. Another method used quantitative
brain water maps to predict age and gender of 44 healthy volunteers aged 23 – 74 years (Neeb
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et al., 2006). A linear discriminant analysis with jackknife cross-validation for age prediction
resulted in a median absolute deviation between real and predicted age of ± 6.3 years.
Although a number of approaches exist that model the pattern of healthy neuronal aging
using MRI data, to our knowledge neither the influences of di↵erent processing parameters on age
estimation were explored, nor was it used for early detection of abnormal aging processes. Large
discrepancies between the true and estimated age could indicate pathologic structural changes.
Therefore, this work could help to contribute to an early diagnosis and better understanding of
neurodegenerative diseases as well as to a more specific and earlier intervention.
In this paper, we present a framework for automatically and e ciently estimating the age
of healthy subjects from T1-weighted MRI scans using RVM-based regression. To avoid over-
fitting as well as to increase sensitivity and reliability, we combine data from the IXI database
(http://www.brain-development.org) and a second sample (Gaser et al., 1999). In total, data
from over 650 healthy subjects aged between 19 – 86, collected from four di↵erent scanners, were
included. To explore the influence of various parameters on the age estimation framework, sev-
eral analyses on this large database were conducted. We sought to identify the optimal set of
processing parameters when the age of data coming from a new scanner had to be estimated.
Another goal of this study was a comparison of the performance of well-established SVM with
RVM-based regression. SVM require the optimization of a number of parameters (described in
more detail in 2.2.4). We therefore expect RVM to be more stable and less vulnerable to pa-
rameter selection errors than SVM. Due to the “curse of dimensionality”, we expect the age
estimation to be more accurate if the dimensionality of the preprocessed data is reduced by a
dimension reduction method like PCA.
Finally, the age estimation framework will be applied to a clinical sample from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database (www.loni.ucla.edu/ADNI), which includes
T1-weighted images of people with mild AD as well as healthy elderly control subjects. Compared
to the group of healthy subjects, we hypothesized that the AD group would have a systemati-
cally larger gap between the estimated brain age and the true age due to accelerated brain aging
that is presumed to be responsible for the diseased state.
2.2 Methods
2.2.1 Subjects / database
To train and test the age estimation framework with respect to prediction accuracy and relia-
bility, we used brain MR images of healthy subjects from the publicly accessible IXI database
(http://www.brain-development.org) and from our own sample. In February 2009, the IXI
database contained T1 images from 550 normal subjects aged 19 – 86 years, which were col-
lected on three di↵erent scanners (Philips 1.5T, General Electric 1.5T, Philips 3T). The subjects
were pseudo-randomly split into a training sample, which was used to generate the regression
models in relevance vector regression (RVR) and support vector regression (SVR), and a test
sample: after sorting the subjects by age, every fourth subject entered the test sample. Since
three subjects, for whom no age was given, had to be excluded, the training sample “TRAIN1–
3” consisted of 410 subjects, and the first test sample (“TEST1–3”) consisted of the remaining
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Table 2.1: Characteristics of the subjects in the training groups (TRAIN1–3) and both test samples
(TEST1–3 and TEST4). TRAIN1–3 and TEST1–3 were collected from the IXI database utilizing three
di↵erent scanners, whereas the MRI data of the TEST4 sample were collected on a fourth scanner and
were not used for training.
IXI database (scanners 1–3) Own sample (scanner 4)
TRAIN1–3 TEST1–3 TEST4
No. subjects 410 137 108
Males/Females 184/226 58/79 68/40
Age mean (SD) 48.2 (16.6) 48.0 (17.0) 32.2 (10.0)
Age range 20–86 19–83 20–59
137 subjects from the IXI database, acquired on the three di↵erent scanners mentioned above.
The second test sample (“TEST4”) originally served as a control group in a clinical study (Gaser
et al., 1999). TEST4 contained T1 images from 108 healthy subjects aged 20 – 59 years, which
were obtained on a fourth scanner (Philips 1.5T).
The characteristics of the three groups are given in Table 2.2.1, and the distribution of age
within the training sample and both test samples are shown in Figure 2.1.
2.2.2 Preprocessing of structural data
Preprocessing of the images was done using the SPM8 package (http://www.fil.ion.ucl.
ac.uk/spm) and the VBM8 toolbox (http://dbm.neuro.uni-jena.de). All T1-weighted im-
ages were corrected for bias-field inhomogeneities, then spatially normalized and segmented into
GM, WM, and CSF within the same generative model (Ashburner and Friston, 2005). The seg-
mentation procedure was further extended by accounting for partial volume e↵ects (Tohka et al.,
2004), by applying adaptive maximum a posteriori estimations (Rajapakse et al., 1997), and by
applying hidden Markov random field model (Cuadra et al., 2005) as described by Gaser (2009).
Only GM images were used for the TRAIN1–3 sample and to test the age estimation model. To
make this age estimation framework fast and e cient, the images were additionally processed
with a ne registration (AF) and smoothed with an 8 mm full-width-at-half-maximum (FWHM)
smoothing kernel (S8). In order to reduce data size the spatial resolution was set to 8 mm (R8),
resulting an image size of about 3700 voxels per subject.
Furthermore – for comparison – the images were registered non-linearly (NL), a 4 mm
FWHM smoothing kernel (S4) was used, and spatial resolution was set to 3 mm (R3) and
4 mm (R4). As non-linear spatial normalization, the approach implemented in the new “Segment
toolbox” in SPM8 was used.
2.2.3 Data reduction
Usually, there are high spatial correlations in voxel-based structural images, which probably
lead to redundant voxels. Moreover, not every single voxel is equally relevant for age prediction.
Because of that and due to the “curse of dimensionality”, data reduction or feature selection
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Figure 2.1: Shown is the age distribution within our training group (TRAIN1–3) and both test samples
(TEST1–3 and TEST4). TRAIN1–3 and TEST1–3 were collected from the IXI database utilizing three
di↵erent scanners, whereas the MRI data of TEST4 were collected on a di↵erent scanner (not used for
training). [Figure and legend modified from Franke et al. 2010.]
might be necessary to obtain meaningful results from the pattern recognition analysis (Ash-
burner, 2009; Duchesnay et al., 2007; Guyon and Elissee↵, 2003). Commonly, PCA is conducted
to reduce the dimensionality of the data.
Using the “Matlab Toolbox for Dimensionality Reduction” (version 0.7b; van der Maaten,
2007, 2008), PCA was applied to the preprocessed images of the training sample. Then the two
test samples were reduced using the resulting PCA transformation. Corresponding to the number
of subjects in the training sample, the data finally had a size of 410 principal components per
subject.
2.2.4 Support vector regression (SVR)
The main idea behind SVMs is the transformation of training data from input space into high-
dimensional space – the feature space – via a mapping function   (Bennett and Campbell,
2003; Scho¨lkopf and Smola, 2002). For the purpose of classification, the hyperplane that best
separates the groups is computed within this feature space, resulting in a non-linear decision
boundary within the input space. The best separating hyperplane is found by maximizing the
margin between the two groups. The data points lying on the margin boundaries are called
support vectors since only these are used to specify the optimal separating hyperplane. In the
case of overlapping class distributions, some training data points are allowed to be misclassified,
resulting in some support vectors lying within the margin or on the wrong side of the margin
boundary (soft-margin classification; Bishop, 2006).
For the case of real-valued output functions (rather than just binary outputs as used in clas-
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Figure 2.2: Illustration of (A) SVR and (B) RVR (modified from Bishop, 2006). Data points are shown
as black dots; circles indicate (A) support vectors and (B) relevance vectors, respectively. [Figure and
legend modified from Franke et al. 2010.]
sification), the SV algorithm was generalized to regression estimation (Bennett and Campbell,
2003; Scho¨lkopf and Smola, 2002). In SVR, a function has to be found that fits as many data
points as possible. Analogous to the soft margin in classification, the regression line is surrounded
by a tube. Data points lying within that tube do not influence the course of the regression line.
Data points lying on the edge or outside that tube are called support vectors (Figure 2.2A). The
expansion of the tube can be determined in a variety of ways, with "-SVR and ⌫-SVR being the
most common approaches. In "-SVR, the a priori specified constant " defines the width of the
linear "-insensitive tube around the regression line. Data points falling within this "-insensitive
tube are not penalized, and are therefore not taken as support vectors. In ⌫-SVR, the a priori
specified sparsity parameter ⌫ defines the upper bound on the fraction of support vectors, i.e.,
data points lying outside an "-insensitive tube that is automatically adjusted in width. To con-
trol the behavior of "-SVR and ⌫-SVR, the type of kernel has to be chosen, along with two more
parameters: C, which controls for model complexity, and " or ⌫, respectively. A short overview
of SVM can be found in Bennett and Campbell (2003). More details can be found in Bishop
(2006) or Scho¨lkopf and Smola (2002).
2.2.5 Relevance vector regression (RVR)
RVMs were introduced by Tipping (2000) as a Bayesian alternative to SVMs for obtaining
sparse solutions to pattern recognition tasks. Moreover, they do not su↵er from some limitations
of the SVM as their predictions are being probabilistic rather than binary and do not need the
determination of additional parameters. In contrast to the support vectors in SVM, the relevance
vectors in RVM appear to represent the prototypical examples within the specified classification
or regression task instead of solely representing separating attributes.
Furthermore severe overfitting associated with the maximum likelihood estimation of the
model parameters was avoided by imposing an explicit zero-mean Gaussian prior (Ghosh and
Mujumdar, 2008; Zheng et al., 2008). This prior is a characteristic feature of the RVM, and
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its use results in a vector of independent hyperparameters that reduces the data set (Faul and
Tipping, 2002; Tipping and Faul, 2003; Tipping, 2000). Therefore, in most cases the number of
relevance vectors is much smaller than the number of support vectors (Figure 2.2B).
To control the behavior of the RVR, only the type of kernel has to be chosen. All other
parameters are automatically estimated by the learning procedure itself. More details can be
found in Bishop (2006), Scho¨lkopf and Smola (2002), or Tipping (2000, 2001).
2.2.6 Computing the age estimation model
We used the freely available toolbox “The Spider” (Version 1.71; Weston et al., 2006) running
under Matlab 7.4.0 to compute the final age regression model.
The T1-weighted MRI data of the training sample TRAIN1–3 and both test samples TEST1–3
and TEST4 were preprocessed by applying a ne registration, followed by smoothing with an
FWHM kernel of 8 mm and resampling with spatial resolution of 8 mm (AF S8 R8). The pre-
processed data were reduced using PCA, and the RVR age estimation model was trained using
this reduced data set. The type of kernel was set to be a polynomial of degree 1, due to its fast
convergence rate. We also tested the performance of non-linear kernels. Age estimation did not
improve (results not shown), despite adding at least one more parameter (e.g., kernel width).
Finally, the ages of the subjects in TEST1–3 and TEST4 were estimated (Figure 2.2.6, box 1 ).
To measure the accuracy of the age estimations, we used the mean absolute error:
MAE = 1/n ·Pi |g0i   gi|, (2.1)
with n being the number of subjects in the test sample, gi the real age, and g0i the age
estimated by the regression model. We found MAE to be the most meaningful measure for
assessing the influence of di↵erent parameters. For comparison, the root mean squared error:
RMSE =
h
1/n ·Pi (g0i   gi)2i1/2 (2.2)
as well as the correlation coe cient were calculated. Because of the restricted age range in
the sample TEST4 and a resulting underestimation of the correlations between the real age and
the predicted age, the correlations were corrected following Holmes (1990).
2.2.7 Systematic analyses of di↵erent parameters influencing the age estima-
tion model
We first compared the age estimation accuracies when testing the age estimation model with data
from “known” scanners (i.e., TEST1–3) versus when testing with data from a “new” scanner
(i.e., TEST4; Figure 2.2.6, box 1 ).
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Secondly, in order to explore the ability to generalize across scanners, we included data
from the fourth scanner into the training sample (Figure 2.2.6, box 2 ). To test for the e↵ect
of scanners on prediction accuracy, the whole IXI data set as well as TEST4 was randomly
and separately split into four groups. This resulted in a training set that included 410 randomly
selected subjects from scanners 1–3 (IXI) plus 81 randomly selected subjects from scanner 4, and
a test set including the remaining 137 subjects from the IXI sample as well as the remaining 27
subjects from scanner 4. The age estimation framework was trained two times: In the first run,
the RVR was trained with 410 randomly selected subjects from the IXI sample (scanners 1–3)
only. Then the age of the remaining 137 subjects from the IXI sample and of the 27 randomly
Figure 2.3: Shown is an overview of the six analyses conducted within this age estimation study to
explore the influences of various parameters on age estimation accuracy. [Figure and legend from Franke
et al. 2010.]
[Abbreviations: AF, a ne registration; NL, non-linear registration; S4/S8, smoothing kernel = 4 mm/8 mm; R3/R4/R8,
spatial resolution = 3 mm/4 mm/8 mm; PCA, principal component analysis; TRAIN1–3, training sample; TEST1–3 and
TEST4, test samples; RVR, relevance vector regression; SVR, support vector regression]
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selected subjects of TEST4 was estimated. In the second run, the RVR was trained with the
same 410 IXI subjects as in the first training run plus the randomly selected training sample
from TEST4. Again, age was estimated for the actual test subjects from all four scanners. After
repeating the whole procedure 20 times, the results were averaged over the trials.
Thirdly, the influence of data reduction and di↵erent kernel regression methods was tested
(Figure 2.2.6, box 3 ). For comparison, the age estimation model was also computed using "-SVR
and ⌫-SVR. As before, a polynomial kernel of degree 1 was chosen. Here, the cost parameter C
and the width of the "-tube or ⌫ for "-SVR and ⌫-SVR, respectively, also have to be set. Instead
of performing an exhaustive grid search and cross-validation to find these model parameters, we
followed Cherkassky and Ma (2004) in choosing the size of the "-SVR parameters, resulting in
C = 98 and " = 0.064. With respect to ⌫-SVR, we followed Chalimourda et al. (2004), resulting
in C = 20500 and ⌫ = 0.54. Furthermore, we also used the default values of the toolbox with
C = 1, " = 0.1, and ⌫ = 0.5, respectively.
Fourthly, to explore which type of preprocessing is best for age prediction, we varied three
parameters during preprocessing: (i) a ne (AF) vs. non-linear (NL) registration, (ii) 4 mm (S4)
vs. 8 mm (S8) FWHM smoothing kernel, and (iii) 3 mm (R3), 4 mm (R4) vs. 8 mm (R8) for
spatial resolution. Memory demands forbade spatial resolutions below 3 mm with this very large
subject pool (Figure 2.2.6, box 4 ).
Fifthly, we analyzed the influence of the size of the training data set (i.e., the number
of subjects), comparing the full training sample (“1/1 TRAIN1–3”) against half of the origi-
nal training sample (“1/2 TRAIN1–3”) and against a quarter of the original training sample
(“1/4 TRAIN1–3”) (Figure 2.2.6, box 5 ).
Finally, all the parameter variations examined before were integrated into one analysis to
assess the proportional amount of influence of each parameter considered (Figure 2.2.6, box 6 ).
2.2.8 Application of the age estimation framework to data from the ADNI
database
To test the potential of this age estimation framework to provide clinically relevant predictions,
the age of people with early AD and cognitively normal elderly control subjects was estimated.
This test sample incorporated MRI data obtained from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database (www.loni.ucla.edu/ADNI). The ADNI was launched in 2003 by the
National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengi-
neering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies,
and non-profit organizations as a $60 million, 5-year public-private partnership. The primary
goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron
emission tomography (PET), other biological markers, and clinical and neuropsychological as-
sessment can be combined to measure the progression of mild cognitive impairment (MCI) and
early Alzheimer’s disease (AD). Determination of sensitive and specific markers of very early
AD progression is intended to aid researchers and clinicians to develop new treatments and
monitor their e↵ectiveness as well as to lessen the time and cost of clinical trials. The Principle
Investigator of this initiative is Michael W. Weiner, M.D., VA Medical Center and University of
California, San Francisco. ADNI is the result of e↵orts of many co-investigators from a broad
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Table 2.2: Characteristics of the two groups from the ADNI database used in the application of the age
estimation framework (AD and NO).
ADNI database
AD (CDR = 1) NO (CDR = 0)
No. subjects 102 232
Males/Females 47/55 119/113
Age mean (SD) 75.8 (8.2) 76.0 (5.1)
Age range 55–88 60–90
range of academic institutions and private corporations, and subjects have been recruited from
over 50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit 800 adults, ages
55 to 90 years, to participate in the research – approximately 200 cognitively normal older indi-
viduals to be followed for 3 years, 400 people with MCI to be followed for 3 years, and 200 people
with early AD to be followed for 2 years. For up-to-date information, see www.adni-info.org.
To compare the age estimations of people with early AD and cognitively normal elderly
subjects, two groups were formed and analyzed using the age estimation framework. The AD
group included T1-weighted images of subjects who had a global Clinical Dementia Rating Scale
(CDR; Morris, 1993) score of 1 at baseline (n = 102; mean Mini-Mental State Examination
(MMSE; Cockrell and Folstein, 1988) score = 22.87). Similarly, the group of healthy controls
(NO) included T1-weighted images of subjects who had a global CDR score of 0 at baseline
(n = 232; mean MMSE score = 29.10). Detailed characteristics of both groups can also be found
in Table 2.2.
In order to get a meaningful comparative deviation score, the di↵erence (or gap) between the
estimated and the true age was computed. This deviation is termed “Brain Age Gap Estimation”
(BrainAGE) score. The mean BrainAGE of the NO group should consequently be zero.
2.3 Results
2.3.1 Performance measures
The age of healthy subjects in both test samples was accurately estimated from their MRI
scans (Table 2.3), with an overall correlation of r = 0.92 and an MAE of just 5 years. The age
prediction tended to be slightly more accurate in TEST1-3, which consisted of subjects scanned
on the same three scanners as the subjects in the training sample, whereas the subjects in TEST4
had been scanned on a scanner that was not included in the training sample. The 95% confidence
interval for the prediction of age was stable along the age range, with no broadening at old age
(cf. age = 20 ± 11.6 years, age = 80 ± 11.7 years; Figure 2.4). Furthermore, a correlation of
r =  0.015 between MAE and the true age indicated no systematical bias in the age estimations
as a function of true ages.
The results did not depend on gender in terms of MAE (5.04 years for male, 4.92 years for
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Figure 2.4: Estimated age and real age are shown for the whole test sample (TEST1–3 + TEST4) with
the confidence interval (light red lines) at a real age of 41 years of ± 11.5 years. The overall correlation
between estimated and real age is r = 0.92, and the overall MAE = 4.98 years. [Figure and legend modified
from Franke et al. 2010.]
female subjects) or correlation (r = 0.92 for both genders). Again, there was no correlation
between estimation accuracy and true age for either gender (male: r = 0.03; female: r =  0.05).
The most important features in the MRI data that were used by the RVR for estimating the
age are shown in Figure 2.5.
2.3.2 Influence of di↵erent scanners
As shown in the first analysis, estimating the age from MRI scans after training an RVR yields
highly accurate predictions, even for completely new data from another scanner. To analyze
the influence of scanners on the accuracy of age estimation, the analysis described in section
Table 2.3: Performance measures of the age estimation model for TEST1–3 and TEST4. Results indicate
that the age of the healthy subjects in both test samples could be accurately estimated from MRI scans.
TEST1–3 TEST4 TEST1–3 + TEST4
Mean absolute error (MAE) 4.61 5.44 4.98
Root mean squared error (RMSE) 5.90 6.73 6.28
Correlation (r) 0.94 0.89 0.92
Confidence interval (at overall mean age of 41 years) ± 10.7 ± 11.7 ± 11.5
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Figure 2.5: To illustrate the most important features that were used by the RVR for estimating the
age based on MRI data, weights below the 5th and above the 95th quartile are displayed, overlaid on the
normalized mean image of TRAIN1–3. Color scale indicates the weight (i.e., the importance of the voxel
location for regression). [Figure and legend from Franke et al. 2010.]
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Figure 2.6: To test for the e↵ect of scanners on prediction accuracy, the IXI data set (scanners 1–3) as
well as sample TEST4 (scanner 4) were randomly split into four groups. The first training run included
75% of the IXI data. For the modified training run, 75% of the TEST4 sample was added to the IXI
training set. Age estimation was performed on the remaining data. Results were averaged over 20 trials
and are shown for each scanner separately. Error bars depict the standard error of the mean (SEM).
[Figure and legend modified from Franke et al. 2010.]
2.2.7 was conducted, in which 75% of the subjects from either scanners 1–3 only or all scanners
were used as the training group. After averaging the results from 20 trials, no di↵erence in
estimation accuracy was found between both training runs. When analyzing scanners separately,
the accuracy of age prediction varied only slightly between individual scanners (Figure 2.6).
2.3.3 Impact of regression methods and data reduction
Because "-SVR and ⌫-SVR are kernel methods that are more common than RVR, it is desir-
able to investigate the di↵erences between the performances of all three methods. Furthermore,
dimensionality reduction via PCA may also influence the accuracy of age estimation.
As summarized in Table 2.4, age estimation tended to be more accurate when the dimen-
sionality of the data was reduced to 410 principal components and RVR was used for model
calculation (also see Figure 2.7). On the other hand, especially when using principal compo-
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Table 2.4: Results of training and testing the age estimation model utilizing di↵erent regression methods,
each with and without dimension reduction via PCA. MAE (in years) is shown, with the best results in
bold.
TEST1–3 TEST4 TEST1–3 + TEST4
RVR PCA 4.61 5.44 4.98
noPCA 4.96 5.57 5.23
"-SVR PCA 4.85 5.42 5.10
(C = 98; " = 0.064) noPCA 4.85 5.51 5.14
⌫-SVR PCA 4.85 5.51 5.14
(C = 20500; ⌫ = 0.54) noPCA 4.85 5.51 5.14
"-SVR (default) PCA 9.82 5.97 8.12
(C = 1; " = 0.1) noPCA 4.76 5.39 5.04
⌫-SVR (default) PCA 11.06 6.38 9.00
(C = 1; ⌫ = 0.5) noPCA 4.72 5.36 5.00
nents, the performance of "-SVR and ⌫-SVR was not stable but depended heavily on the choice
of its parameters. While using sample-dependent parameters as proposed in Cherkassky and Ma
(2004) and Chalimourda et al. (2004), the MAEs reached up to 5 years and thus were comparable
to the MAE from the RVR model. Without using sample-dependent parameters or performing
a grid search to find optimal parameters for "-SVR and ⌫-SVR, but instead using the default
values (i.e., C = 1; " = 0.1 and ⌫ = 0.5, respectively), the MAE for estimating the age with
reduced data was substantially worse – scoring 8 and 9 years, respectively (Figure 2.7).
Taking a closer look at the number of principal components used in training and testing
the age estimation model (using RVR), the accuracy continuously improved with an increasing
number of principal components, with a convergence to the smallest MAE at about the first
350 principal components (Figure 2.8). Severe overfitting was prevented due to the inherent
characteristics of RVM.
Furthermore, training and testing the age estimation model utilizing RVR or SVR was com-
putationally fast, with a processing time for training and testing the reduced data of only a few
seconds on MAC OS X, Version 10.4.11, Dual 2.5 GHz PowerPC G5 (Figure 2.9).
2.3.4 Comparison of variations in data preprocessing (a ne vs. modulated,
smoothing, and spatial resolution)
With respect to preprocessing of the MRI data, we compared di↵erent kinds of registration
(AF versus NL), di↵erent sizes of the smoothing kernel (S4 versus S8), and di↵erent spatial
resolutions (R3, R4, and R8). The MAE of the age estimations ranged from 4.98 to 5.45 years,
and the most accurate predictions occurred with a ne registration and a smoothing kernel of
8 mm. The influence of spatial resolution was negligible (Table 2.5, Figure 2.10).
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Figure 2.7: Age estimation tended to be best when the dimensionality of the data was reduced via PCA
(dark blue) and RVR was used for model calculation. With the reduced data, the performance of "-SVR
and ⌫-SVR was not stable but depended heavily on the choice of parameters. Error bars depict the SEM.
[Figure and legend modified from Franke et al. 2010.]
Table 2.5: Results of analyses with respect to registration method [a ne (AF) vs. non-linear (NL)], size
of the smoothing kernel [4 mm (S4) vs. 8 mm (S8)], and spatial resolution [3 mm (R3), 4 mm (R4), 8
mm (R8)]. Results are shown in terms of MAE (in years). The best results are marked in bold.
Registration NL AF
Smoothing kernel S4 S4 S8
Spatial resolution R3 R4 R8 R3 R4 R8 R3 R4 R8
TEST1–3 5.02 5.05 5.28 5.21 5.18 5.19 4.67 4.72 4.61
TEST4 4.98 4.96 5.19 5.30 5.38 5.77 5.49 5.54 5.44
TEST1–3 + TEST4 5.00 5.01 5.24 5.25 5.27 5.45 5.03 5.08 4.98
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Figure 2.8: The accuracy of the age estimation model (using RVR) continuously improves with an
increasing number of principal components, observing a convergence to the smallest MAE at about
the first 350 principal components. MAEs shown for each test sample separately as well as for both test
samples together (purple). Star symbols represent MAEs resulting from training the age estimation model
without data reduction, but utilizing the preprocessed MRI data. [Figure and legend modified from Franke
et al. 2010.]
2.3.5 Influence of the size of training data
Figure 2.11 illustrates that the size of the training data set had a strong e↵ect on the accuracy
of age estimation. Whereas the full data set (n = 410 subjects) produced an MAE of less than
5 years, using only one half (n = 205) or a quarter (n = 103) of the training data set for training
the age estimation model produced MAEs of 5.2 and 5.6 years, respectively.
2.3.6 Comparing the influence of the various parameters
Merging the set of all adjustable parameters and methodologies, it can be seen in Figure 2.12
that the accuracy of age estimation depended mostly on the number of subjects used for training.
The method for preprocessing the T1-weighted MRI images also showed a strong influence on
the accuracy of age estimation, again favoring a ne registration with a broad smoothing kernel.
Furthermore, reducing the dimensionality of data via PCA also had a moderate e↵ect on the
MAE.
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Figure 2.9: Training and testing the age estimation model utilizing RVR or SVR needed only a few
seconds on MAC OS X, Version 10.4.11, Dual 2.5 GHz PowerPC G5 if the dimensions were reduced to
410 principal components (dark blue). [Figure and legend modified from Franke et al. 2010.]
2.3.7 Estimating the age of patients with early AD
The age estimation framework was applied to T1-weighted MRI images of the NO group and
the AD group sampled from the ADNI database. The BrainAGE score was calculated for each
subject. For the AD group, the mean BrainAGE score was 10 years, implying a systematically
higher estimated than true age based on the MRI data (Figure 2.13). This deviation was highly
significant (p < 0.001, df = 332).
2.4 Discussion
For estimating the age of healthy subjects from T1-weighted MRI scans, we propose a framework
that includes automatic preprocessing of the images, dimension reduction via PCA, training of
an RVM for regression with a polynomial kernel of degree 1, and finally estimating the age of
the subjects from the two test samples TEST1–3 and TEST4. This age estimating framework
turns out to be a straightforward method to accurately and reliably estimate age with as little
preprocessing and parameter optimization as possible. The additional challenge consisted of
combining images from three di↵erent scanners for training and testing with an additional testing
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Figure 2.10: Comparing the di↵erent kinds of registration [a ne (AF) vs. non-linear (NL)], di↵erent
sizes of the smoothing kernel [4 mm (S4) vs. 8 mm (S8)], and di↵erent spatial resolutions [3 mm (R3),
4 mm (R4), 8 mm (R8)], the MAE of age estimation changes only slightly, with the most accurate age
estimation obtained for a ne registration and a smoothing kernel of 8 mm (dark blue). Error bars depict
the SEM. [Figure and legend modified from Franke et al. 2010.]
set from a fourth scanner not included during the training step.
Using MRI data from more than 650 healthy subjects aged between 19 – 86 and scanned
on di↵erent scanners, the age estimation with RVR showed excellent performance for both test
samples, with an overall MAE of only 5 years and a correlation of r = 0.92 between the estimated
and the real age. Although the data in TEST4 were collected on a scanner that was not included
in the training step, the performance measures for age estimation showed only minor di↵erences
to those of TEST1–3. We did not detect any systematical bias in the age estimation with older
age or gender.
Including data from the fourth “unknown” scanner into the training sample did not improve
the overall accuracy of age prediction. This could be due to the age range of the samples.
TEST4 comprised data from subjects aged between 20 – 59 years, which were already frequently
represented in the original training sample TRAIN1–3. On the other hand, adding data from
healthy subjects with an age range of 60 – 90 would probably have had a stronger influence
on the performance of RVR. Thus, with respect to combining data from di↵erent scanners, our
results are in line with those of Klo¨ppel et al. (2008b). They indicate that the e↵ect of scanner is
su ciently di↵erent from that of the aging process that they could be separated by the regression
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Figure 2.11: Shown is the influence of the size of trainings data set. Whereas the full data
(1/1 TRAIN1–3) set produced an MAE of less than 5 years, taking only one half (1/2 TRAIN1–3)
or a quarter (1/4 TRAIN1–3) of the training data set for computing the age estimation model produced
MAEs of 5.2 and 5.6 years, respectively. Error bars depict the SEM. [Figure and legend modified from Franke
et al. 2010.]
method. These encouraging results suggest this framework as an accurate, scanner-independent,
and e cient method for age estimation in healthy subjects.
In RVR, the type of kernel is the only parameter that has to be defined by the user. In
contrast, in "-SVR and ⌫-SVR, another two parameters have to be chosen and can decrease the
performance if they are not optimized for the specific sample. Age estimation with RVR tends
to be slightly better with PCA than without. Furthermore, using the principal components for
training and testing with RVR only needed a few seconds and thus is significantly faster than
using the full original data set (Figure 2.9).
We decided to use PCA for data reduction because of several reasons: it is a rather simple
and commonly used method, and a number of fast implementations exist that are compatible
with large data sets. Furthermore, when testing other data reduction or feature selection meth-
ods (e.g., Recursive Feature Elimination; Guyon et al., 2002; Guyon and Elissee↵, 2003), we
did not observe any improvement in accuracy of age estimation. Also, van der Maaten (2007)
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Figure 2.12: Integrating the influences of the various parameters: the accuracy of age estimation es-
sentially depends on the number of subjects used for training the age estimation model (blue lines: full
training set TRAIN1–3); the method for preprocessing the T1-weighted MRI images also showed a strong
influence on the accuracy of age estimation; and data reduction via PCA only had a moderate e↵ect on
the MAE. [Figure and legend modified from Franke et al. 2010.]
reported that the results of their experiments on artificial and natural data sets indicate no clear
improvement of non-linear techniques (for example, Isomap or Laplacian Eigenmaps and others)
over traditional PCA.
The number of training samples was found to have the strongest influence on the accuracy of
age prediction. Our results suggest that the preprocessing of the T1-weighted MRI images can
be done fairly rapidly by performing an a ne registration only with a large smoothing kernel
(e.g., 8 mm). Furthermore, given limited computing time and memory, a coarse spatial resolution
(e.g., 8 mm) can be used without losing estimation accuracy. A dimensionality reduction of the
data can be conducted using PCA, which tends to improve the accuracy and at the same time
speeds up the computing of the RVR model and estimating the age values of the test subjects.
Finally, our age estimation framework has the potential to provide clinically relevant infor-
mation. With a mean BrainAGE score of +10 years, the subjects with early AD showed signs
of accelerated brain aging.
In conclusion, our age estimation framework could potentially help to recognize or indicate
faster brain atrophy before the onset of clinical symptoms, thus contributing to an early diag-
nosis of neurodegenerative diseases and facilitate early treatment or a preventative intervention.
Depending on the availability of subject data, future explorations could include applying this
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Figure 2.13: Shown are box plots with BrainAGE scores (in years) for the two samples from the ADNI
database (AD with CDR = 1, NO with CDR = 0). The gray boxes contain the values between the 25th
and 75th percentiles of the samples, including the median (red line). Lines extending above and below
each box symbolize data within 1.5 times the interquartile range (outliers are displayed with a red +).
The width of the boxes depends on the sample size. [Figure and legend modified from Franke et al. 2010.]
framework to other neurodegenerative diseases, evaluating the therapeutic e↵ect of drugs or
other treatment modalities, and to predict either the severity of symptoms or the possible rate
of cognitive decline.
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Abstract
We recently proposed a novel method that aggregates the multidimensional aging pattern across
the brain to a single value. This method proved to provide stable and reliable estimates of brain
aging – even across di↵erent scanners. While investigating longitudinal changes in BrainAGE
in about 400 elderly subjects, we discovered that patients with Alzheimer’s disease (AD) and
subjects who had converted to AD within 3 years showed accelerated brain atrophy by +6 years
at baseline. An additional increase in BrainAGE accumulated to a score of about +9 years
during follow-up. Accelerated brain aging was related to prospective cognitive decline and disease
severity. In conclusion, the BrainAGE framework indicates discrepancies in brain aging and could
thus serve as an indicator for cognitive functioning in the future.
3.1 Introduction
During normal brain development and aging, the brain is a↵ected by progressive (e.g., cell growth
and myelination) and by regressive (e.g., cell death and atrophy) neuronal processes (Silk and
Wood, 2011). Those processes have been found to follow a specific pattern, with gray matter
(GM) volume increasing in the first years of life and thereafter decreasing continuously; and
with white matter (WM) volume increasing steadily until around the age of 20 when it plateaus
(Good et al., 2001; Pfe↵erbaum et al., 1994). Healthy brain aging has been found to follow a
specific heterogeneous and complex pattern of atrophy across the adult lifespan (Good et al.,
2001), with normal age-related GM decline being inversely related to the phylogenetic origin of
each respective region, i.e., younger structures being the last to mature as well as being more
vulnerable to neurodegeneration (Terribilli et al., 2011; Toga et al., 2006).
With the growing number of studies that have investigated both normal and abnormal age-
related brain changes, most major neuropsychiatric disorders are now thought to arise due to
deviations from normal brain development (Gogtay and Thompson, 2010). Also diseases such
as Alzheimer’s disease (AD) and schizophrenia alter brain structures in diverse and abnormal
modes (Ashburner et al., 2003; Meda et al., 2008). AD in particular is widely assumed to reflect
accelerated aging (Cao et al., 2010; Jones et al., 2011; Saetre et al., 2011), with accelerated age-
related changes in brain atrophy being already evident at the stage of mild cognitive impairment
(MCI), i.e., the prodromal stage of AD (Driscoll et al., 2009; Spulber et al., 2010). Additional
evidence for this view was recently provided by showing that the atrophied regions detected
in AD patients are largely overlapping with regions showing a normal age-related decline in
age-matched healthy control subjects (Dukart et al., 2011).
Given the widespread but well-ordered brain tissue loss that occurs as a function of age-based
processes, a straight-forward and e cient solution might be to model healthy brain aging in or-
der to subsequently identify abnormal aging processes and accelerated brain atrophy before the
onset of upcoming clinical symptoms. Recently, we introduced a new approach based on struc-
tural magnet resonance imaging (MRI) data that enables to reliably estimate the brain age of
any given subject (Franke et al., 2010). By employing kernel regression methods in a large train-
ing database, the complex, multidimensional aging patterns across the whole brain are detected
and finally aggregated to a single value, i.e., the estimated brain age (Figure 1.4A, page 13). The
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individual discrepancies between estimated and chronological age were termed “Brain Age Gap
Estimation” (BrainAGE) score, with observed di↵erences in BrainAGE scores being interpreted
as originating from structural brain changes that show the pattern of accelerated (or deceler-
ated) aging. Consequently, although only one MRI scan per subject is employed, the degree of
acceleration or deceleration of brain aging can be quantified directly in terms of years, allowing
a wide range of analyses and predictions on an individual level. For example, if a 70-year-old
individual has a deviating BrainAGE score of +5 years, this means that this individual shows
the typical atrophy pattern of a 75-year-old individual (Figure 1.4B, page 13). The framework
comprises well-established and fully automatic processing steps of the MRI data, combines data
from di↵erent scanners, and accurately estimates the age of healthy individuals with a correlation
of r = 0.92 between estimated and chronological age. Furthermore, this brain-age estimation
model has showed its potential to provide clinically relevant information by reporting a sta-
tistically significant, positive deviation of 10 years between estimated and chronological age in
AD patients from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database, indicating
structural brain changes that show the pattern of accelerated aging (Franke et al., 2010). Ad-
ditionally, a slightly modified BrainAGE approach recently provided a reliable reference curve
based on structural MRI data, allowing for the prediction of structural brain maturation and a
fast identification of developmental delays in childhood and adolescence (Franke et al., 2012b).
By implementing this new method of brain-age estimation, our present studies further ana-
lyze the stability and reliability of the BrainAGE approach, utilizing two subsamples that have
(1) a short delay between two scans of the same subject on the same scanner (1.5T) as well as
(2) two scans of the same subjects with two di↵erent field strengths (1.5T and 3.0T). Second,
within a follow-up period of up to 4 years we explored the patterns of longitudinal changes
in individual BrainAGE and quantified about 400 cognitively normal, MCI, and AD subjects.
Further, we related discrepancies in brain aging to prospective cognitive functioning and disease
severity.
3.2 Methods
3.2.1 ADNI Database
Part of the data used in the preparation of this article were obtained from the ADNI database
(http://adni.loni.ucla.edu). The ADNI was launched in 2003 by the National Institute on
Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the
Food and Drug Administration (FDA), private pharmaceutical companies, and non-profit orga-
nizations, as a $60 million, 5-year public-private partnership. The primary goal of ADNI was to
test whether serial MRI, positron emission tomography (PET), other biological markers as well
as clinical and neuropsychological assessment can be combined to measure the progression of
MCI and early AD. Determination of sensitive and specific markers of very early AD progres-
sion should aid researchers and clinicians in developing new treatments and monitoring their
e↵ectiveness as well as lessening the time and cost of clinical trials.
The principal investigator of this initiative is Michael W. Weiner, MD, VA Medical Center
and University of California, San Francisco. ADNI is the result of e↵orts of many coinvestigators
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Table 3.1: Characteristics of the subjects in the training group (IXI) and both test samples (OASIS and
ADNI) double-scanned within a short delay (< 90 days).
Training sample Test samples
IXI OASIS AD
No. subjects 560 20 60
Males/Females 249/311 8/12 22/38
Age mean (SD) 48.6 (16.5) 23.4 (4.0) 75.2 (4.8)
Age range 20–86 19–34 60–87
No. of MRI scanners (1.5T/3T) 2/1 1/0 26/26
from a broad range of academic institutions and private corporations, and subjects have been
recruited from over 50 sites across the United States and Canada. The initial goal of ADNI was
to recruit 800 adults, aged 55 – 90, to participate in the research; approximately 200 cognitively
normal older individuals to be followed for 3 years; 400 people with MCI to be followed for
3 years; and 200 people with early AD to be followed for 2 years. For up-to-date information,
see http://www.adni-info.org.
3.2.2 Subjects
To train the age estimation framework, we used T1-weighted MRI data of 560 healthy subjects
(249 males) from the publicly accessible IXI cohort (http://www.brain-development.org; data
downloaded in September 2011) aged 20 – 86 years, which were collected on three di↵erent
scanners (Philips 1.5T, General Electric 1.5T, Philips 3.0T).
Before analyzing the individual patterns of longitudinal BrainAGE changes, the stability of
BrainAGE estimations within the same subjects were explored using two di↵erent subsamples.
The first test sample included structural MRI data of 20 healthy subjects (aged 19 – 34 years)
from the Open Access Series of Imaging Studies database (OASIS; http://www.oasis-brains.
org; Marcus et al., 2007), for whom a short-delay (less than 90 days) double scan on the same
scanner was available (Siemens 1.5T). The second test sample included 1.5T as well as 3.0T struc-
tural MRI data (acquired within a short delay) of 60 healthy non-demented elderly subjects (aged
60 – 87 years) from the ADNI database (data downloaded in May 2010). The characteristics of
all three samples are given in Table 3.1.
To investigate the longitudinal pattern of BrainAGE changes in healthy aging, MCI, and
AD, a third test sample included all subjects from the ADNI database for whom at least the
baseline scan and one follow-up scan were available (1.5T). Adopting the diagnostic classification
at baseline and follow-up, subjects were grouped as (i) NO (healthy subjects) if diagnosis was
NO at baseline and 3-year follow-up (n = 108); (ii) sMCI (stable MCI) if diagnosis was MCI
at baseline and 3-year follow-up (n = 36); (iii) pMCI (progressive MCI) if diagnosis was MCI
at baseline and AD at some follow-up, without reversion to MCI or NO (n = 112); (iv) AD
patients if diagnosis was AD at baseline, without reversion (n = 150). For further analyses we
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Table 3.2: Characteristics of the ADNI test sample for longitudinal analyses.
NO sMCI pMCI AD
Baseline No. subjects 108 36 112 150
Males/Females 61/47 30/6 67/45 76/74
Age mean (SD) 75.6 (5.0) 77.0 (6.1) 74.5 (7.4) 74.6 (7.6)
MMSE mean (SD) 29.22 (0.89) 27.42 (1.87) 26.62 (1.75) 23.45 (1.95)
CDR mean (SD) 0.00 (0.00) 0.50 (0.00) 0.50 (0.00) 0.73 (0.25)
ADAS mean (SD) 8.84 (3.84) 17.29 (5.88) 21.77 (5.70) 28.78 (7.85)
Follow-up No. scans (SD) 5.02 (0.77) 5.86 (0.87) 5.20 (1.38) 3.45 (0.74)
Follow-up duration in days (SD) 1194 (261) 1114 (244) 969 (360) 609 (222)
Age at last scan (SD) 78.9 (5.0) 80.1 (6.0) 77.2 (7.6) 76.3 (7.7)
MMSE mean (SD) 29.01 (1.27) 27.11 (2.63) 21.62 (4.28) 19.28 (5.64)
CDR mean (SD) 0.06 (0.16) 0.49 (0.15) 0.92 (0.42) 1.27 (0.67)
ADAS mean (SD) 10.11 (5.44) 17.64 (6.48) 32.53 (9.48) 38.14 (12.14)
[Abbreviations: AD, Alzheimer’s disease; ADAS, Alzheimer’s Disease Assessment Scale; CDR, clinical dementia rate; MMSE,
Mini- Mental State Examination; NO, healthy control subjects; pMCI, progressive mild cognitive impairment; SD, standard
deviation; sMCI, stable mild cognitive impairment.]
used baseline and follow-up test scores of the cognitive scales: Alzheimer’s Disease Assessment
Scale (ADAS; range 0 – 85, with higher test scores being related to worse cognitive functioning;
Mohs and Cohen, 1988; Mohs, 1996), global Clinical Dementia Rating Scale (CDR; range 0 – 3,
with 0 denoting cognitively healthy, 0.5 denoting mild cognitive impairments, and a score of
1 or above denoting AD; Morris, 1993), and Mini-Mental State Examination (MMSE; range
0 – 30, with lower scores being related to higher disease severity; Cockrell and Folstein, 1988).
The baseline and follow-up characteristics of this test sample are given in Table 3.2.
3.2.3 Preprocessing of MRI Data and Data Reduction
Preprocessing of the T1-weighted images was done using the SPM8 package (http://www.fil.
ion.ucl.ac.uk/spm) and the VBM8 toolbox (http://dbm.neuro.uni-jena.de), running un-
derMatlab. All T1-weighted images were corrected for bias-field inhomogeneities, then spatially
normalized and segmented into GM, WM, and cerebrospinal fluid (CSF) within the same genera-
tive model (Ashburner and Friston, 2005). The segmentation procedure was further extended by
accounting for partial volume e↵ects (Tohka et al., 2004), by applying adaptive maximum a pos-
teriori estimations (Rajapakse et al., 1997), and by using a hidden Markov random field model
(Cuadra et al., 2005) as described previously (Gaser, 2009). The images were processed with
a ne registration and smoothed with 4-mm full-width-at-half-maximum smoothing kernels.
3.2.4 BrainAGE Framework
The BrainAGE framework utilizes a high-dimensional pattern recognition method, i.e., relevance
vector regression (RVR; Tipping, 2001), to model healthy brain aging. RVR was introduced by
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Tipping (2000) as a Bayesian alternative to support vector machines (SVM), but is easier to
use since all model parameters are automatically estimated by the learning procedure itself.
More details can be found in Bishop (2006), Scho¨lkopf and Smola (2002), and Tipping (2000).
Recently, the BrainAGE framework proved to be a reliable, scanner-independent, and e cient
method for age estimation in healthy subjects (Franke et al., 2010). It resulted in a correlation
of r = 0.92 between the estimated and the real age in the test samples, and a mean absolute
error (MAE) of 5 years. Furthermore, the study identified the number of training samples as the
critical factor for prediction accuracy.
In general, the age regression model is trained with the chronological age and preprocessed
whole brain structural MRI data of the training sample, resulting in a complex model of healthy
brain aging (Figure 1.4A, left). Subsequently, the brain age of a test subject can be estimated
using the individual tissue-classified MRI data, aggregating the complex, multidimensional aging
pattern across the whole brain into one single value (Figure 1.4A, right; page 13). The di↵erence
between estimated and chronological age results in the BrainAGE score, which consequently
directly quantifies the amount of acceleration or deceleration in brain aging (Figure 1.4B; page
13). For training the model as well as for predicting individual brain ages, we used “The Spider”
(http://www.kyb.mpg.de/bs/people/spider/main.html), a freely available toolbox running
under Matlab. For more detailed information please refer to Franke et al. (2010).
Within this study, the linear combination of whole brain GM and WM images were used
to train the BrainAGE framework. Data reduction was performed by applying principal com-
ponent analysis (PCA), utilizing the “Matlab Toolbox for Dimensionality Reduction”(http:
//ict.ewi.tudelft.nl/~lvandermaaten/Home.html). PCA was performed only on the train-
ing sample. The estimated transformation parameters were subsequently applied to the test
samples, allowing estimation of individual brain ages based on baseline MRI data. The di↵er-
ence between the estimated and the chronological age resulted in the BrainAGE score, indicating
accelerated (positive values) or decelerated (negative values) brain aging.
3.2.5 Statistical Analysis
In the first analysis, the intraclass correlation coe cient (ICC; two-way random single measures)
as well as Student’s t-test was calculated for each test sample separately to assess the conformity
and stability of BrainAGE estimations across several MRI scans within a short delay (OASIS)
and across di↵erent scanner field-strengths (ADNI).
In the second analysis, the longitudinal changes in individual BrainAGE scores, which were
corrected for age and gender, were fitted against days from baseline with a multivariate linear
regression model. Baseline BrainAGE scores, BrainAGE scores at last visit, and longitudinal
changes in BrainAGE were compared among the four diagnostic groups using an analysis of
variance (ANOVA). Post-hoc analyses (with Bonferroni adjustment to compensate for multiple
comparisons) were conducted to further explore significant group di↵erences. The relationship
between BrainAGE scores and cognitive scales (i.e., MMSE, CDR, ADAS) were explored using
Pearson’s linear correlation coe cients. ICC was calculated using SPSS. All other statistical
testing was performed using Matlab.
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Figure 3.1: Unadjusted (left panel) and o↵set-adjusted (right panel) BrainAGE scores for double-
scanned OASIS subjects on the same scanner within a short delay. ICC between the BrainAGE scores
calculated from the 1st and 2nd scan was 0.93. [Figure and legend from Franke et al. 2012a.]
3.3 Results
3.3.1 Stability of BrainAGE Estimations
The BrainAGE estimations within the same subjects proved to be stable across a short delay
between two scans as well as across scanners. In the OASIS subsample, in which the subjects had
a short delay between two scans on the same scanner (1.5T), the brain-age estimations resulted
in mean (SD) raw BrainAGE scores of 13.8 (6.1) years for the 1st and 12.8 (5.6) years for the
2nd scan (Figure 3.1, left). The raw BrainAGE scores derived from the 1st as well as 2nd scan
significantly di↵ered from a zero mean (p < 0.001), but not among each other (p = 0.60). The
correlation between the raw BrainAGE scores derived from the 1st and 2nd scan data resulted
in r = 0.93 (p < 0.001). Thus, the results suggest a systematical data-specific o↵set at each of
both scanning time points. For illustration reasons and/or better interpretability of the results,
this o↵set can be easily adjusted by a linear shift, i.e., setting the BrainAGE scores to a zero
group mean (Figure 3.1, right). Linearly adjusting for the o↵set at each scanning time point
separately, resulted in a correlation between raw and adjusted BrainAGE scores of r = 0.996
(p < 0.001). The ICC between the BrainAGE scores calculated from the 1st and 2nd scan was
0.93 [95% confidence interval (CI): 0.83  0.97], demonstrating strong stability of the estimated
BrainAGE scores across several MRI scans.
The ADNI subsample, which included only non-demented subjects who had two baseline
scans from MRI scanners of two di↵erent field strengths (1.5T and 3.0T) showed mean (SD)
raw BrainAGE scores of  5.9 (7.0) years for the 1.5T data and  9.1 (6.6) years for the 3.0T
data (Figure 3.2, left), with a correlation between both scans of r = 0.91 (p < 0.001). The
raw BrainAGE scores derived from the 1.5T as well as 3.0T data significantly di↵ered from
a zero mean (p < 0.001). These results additionally suggest a strong dependency of brain-age
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Figure 3.2: Unadjusted (left panel) and o↵set-adjusted (right panel) BrainAGE scores for double-
scanned ADNI subjects on 1.5T and 3.0T scanner within a short delay. ICC between the BrainAGE
scores calculated from the 1.5T and 3.0T scan was 0.90. [Figure and legend from Franke et al. 2012a.]
estimation on field strength, with 1.5T MRI data resulting in larger BrainAGE scores than
those derived with 3.0T MRI data. Again, this o↵set can be easily adjusted by a linear shift as
described above (Figure 3.1, right). After linearly adjusting for the field strength-specific o↵-set,
Student’s t-test resulted in no di↵erence between the BrainAGE scores calculated from the 1.5T
and 3.0T scan (p = 1.00). ICC between the BrainAGE scores calculated from the 1.5T and
3.0T scan was 0.90 [CI: 0.84  0.94], demonstrating strong stability of the estimated BrainAGE
scores across di↵erent field strengths. Taken together, these results suggest that the BrainAGE
framework reliably estimates individual brain age based on structural MRI data.
3.3.2 Longitudinal BrainAGE Estimation
In the longitudinal ADNI sample, the baseline BrainAGE scores di↵ered among the four groups
(F = 26.8, p < 0.001). For better interpretability, all individual BrainAGE scores were ad-
justed by a linear shift determined in the NO group (as described in section 3.3.1). Thus,
the baseline BrainAGE scores resulted in the following group means: NO =  0.30 years,
sMCI =  0.48 years, pMCI = 6.19 years, and AD = 6.67 years (Figure 3.3A). Post-hoc t-tests
showed significant di↵erences between NO/sMCI vs. pMCI/AD (p < 0.05), suggesting structural
brain changes that show the pattern of accelerated aging in the pMCI and AD groups. Regarding
NO and sMCI subjects, the estimated brain age at baseline did not di↵er significantly from the
chronological age (p = 0.61 in both groups).
The BrainAGE scores remained stable for the NO and the sMCI groups across the follow-
up period of up to 4 years, but increased in the pMCI and AD groups, suggesting additional
acceleration in brain aging in the pMCI and AD groups. The fit of the longitudinal changes
in BrainAGE resulted in the following changing rates (BrainAGE years per follow-up year):
NO = 0.12, sMCI = 0.07, pMCI = 1.05, and AD = 1.51 (Figure 3.4). These rates di↵ered
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Figure 3.3: Box plots of (A) baseline BrainAGE scores and (B) BrainAGE scores of last MRI scans for
all diagnostic groups. Post-hoc t-tests showed significant di↵erences between NO/sMCI vs. pMCI/AD
(p < 0.05) at both time measurements. The gray boxes contain the values between the 25th and 75th
percentiles of the samples, including the median (gray line). Lines extending above and below each box
symbolize data within 1.5 times the interquartile range (outliers are displayed with a +). The width of
the boxes depends on the sample size. [Figure and legend from Franke et al. 2012a.]
among the groups (F = 23.1, p < 0.001), with post-hoc t-tests showing significant di↵er-
ences between NO/sMCI vs. pMCI/AD (p < 0.05). At the last MRI scan of each subject, the
BrainAGE scores also di↵ered among the groups (F = 44.0, p < 0.001), resulting in the follow-
ing: NO =  0.06 years, sMCI =  0.38 years, pMCI = 8.96 years, and AD = 9.02 years (Figure
3.3B). Again, post-hoc t-tests showed significant di↵erences between NO/sMCI vs. pMCI/AD
(p < 0.05). Regarding NO and sMCI subjects, the estimated brain age at baseline did not di↵er
significantly from the chronological age (p = 0.92 and p = 0.68, respectively).
Taken together, these results suggest that the acceleration in brain aging in pMCI and AD
found at baseline becomes even more accelerated during the next months and years. On the
other hand, the results suggest that brain aging in NO and sMCI remained stable during the
follow-up period of 4 years, showing only normal age-related atrophy. Across the whole sam-
ple, the BrainAGE scores at baseline were moderately correlated with cognitive functioning
and clinical disease severity up to 4 years later (Table 3.3), with larger BrainAGE scores being
related to worse cognitive functioning and more severe clinical symptoms (r = 0.39    0.46).
The BrainAGE scores based on the last MRI scan correlated even slightly stronger with cog-
nitive scores and clinical severity of the last follow-up visit (r = 0.46    0.55). The changes
in BrainAGE scores were also related to the individual changes in all of the three scores
(r = 0.27    0.33). These results denote a close relationship between accelerated brain ag-
ing and prospective worsening of cognitive functioning within the whole sample, i.e., within the
full variance of cognitive as well as BrainAGE scores.
Even more interesting, when analyzing each diagnostic group separately, we found these
relationships between BrainAGE and cognitive as well as severity scores were only in the pMCI
and AD groups, but not in sMCI and NO groups (Table 3.3). In pMCI, the strongest correlation
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Figure 3.4: Longitudinal changes in BrainAGE scores for NO, sMCI, pMCI, and AD. Thin lines represent
individual changes in BrainAGE over time; thick lines indicate estimated average changes for each group.
Post-hoc t-tests showed significant di↵erences in the longitudinal BrainAGE changes between NO/sMCI
vs. pMCI/AD (p < 0.05). [Figure and legend from Franke et al. 2012a.]
with BrainAGE was found in ADAS (r = 0.40, p < 0.001), which is a rather cognitive scale. In
AD, the strongest correlation with BrainAGE was found in MMSE (r =  0.46, p < 0.001), which
is commonly used to measure disease severity in AD. These results strongly support the recent
result of profound accelerated brain aging being related to disease severity, most pronounced in
subjects being already diagnosed with AD, and prospective worsening of cognitive functioning,
most pronounced in pMCI subjects.
3.4 Discussion
This study described and implemented a novel MRI-based biomarker, aggregating the com-
plex, multidimensional aging pattern across the whole brain into one single value, i.e., the
BrainAGE score that directly quantifies acceleration or deceleration in individual brain ag-
ing. The BrainAGE framework comprises well-established and fully automated processing of
the T1-weighted MR images and allows one to combine data from di↵erent MRI scanners. With
correlations between chronological age and estimated brain age of r = 0.92 in healthy adults,
aged 20–86 years (Franke et al., 2010), and r = 0.93 in healthy children and adolescents, aged
5–18 years (Franke et al., 2012b), the BrainAGE framework has proved to be a straightfor-
ward method of accurately and reliably estimating brain age with minimal preprocessing and
parameter optimization.
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Table 3.3: Correlation coe cients between BrainAGE and cognitive functioning (ADAS scores) as well as disease severity (MMSE & CDR scores) for the whole
test sample as well as for each diagnostic group separately.
NO sMCI pMCI AD Whole sample
Correlation with baseline BrainAGE score MMSE score at last scan –0.14 0.09 –0.18 –0.38⇤⇤⇤ –0.46⇤⇤⇤
CDR score at last scan –0.04 0.03 0.13 0.24⇤⇤ 0.39⇤⇤⇤
ADAS score at last scan –0.03 –0.24 0.33⇤⇤⇤ 0.31⇤⇤⇤ 0.45⇤⇤⇤
Correlation with BrainAGE score at last scan MMSE score at last scan –0.12 0.01 –0.28⇤⇤ –0.46⇤⇤⇤ –0.55⇤⇤⇤
CDR score at last scan 0.01 –0.09 0.20⇤ 0.30⇤⇤⇤ 0.46⇤⇤⇤
ADAS score at last scan –0.04 –0.10 0.40⇤⇤⇤ 0.37⇤⇤⇤ 0.55⇤⇤⇤
Correlation with change in BrainAGE score MMSE change 0.09 –0.29 –0.23⇤ –0.23⇤⇤ –0.33⇤⇤⇤
(baseline – last scan) CDR change 0.13 –0.27 0.19⇤ 0.19⇤ 0.27⇤⇤⇤
ADAS change –0.10 –0.04 0.29⇤⇤ 0.16⇤ 0.30⇤⇤⇤
[Notes: ⇤p < 0.05, ⇤⇤p < 0.01, ⇤⇤⇤p < 0.001. Bold type = significant correlations, slanted type = whole sample.]
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Most remarkably, although brain maturation in childhood as well as brain aging in late
life comprise very complex, multidimensional, and highly variable processes (Good et al., 2001;
Lebel and Beaulieu, 2011; Lenroot and Giedd, 2006; Wilke and Holland, 2003), the confidence
intervals of estimated brain age did not change as a function of age (Franke et al., 2010, 2012b).
This underlines the great potential of the approach to correctly capture the multidimensional
characteristics of the di↵erent maturational and aging processes occurring in childhood and old
age, respectively.
Here, the BrainAGE framework was trained with whole-brain structural MRI data of about
560 healthy subjects, aged 20 – 86 years. The model of healthy brain aging was then applied
to new data samples. First, the stability of individual BrainAGE scores was examined. With
ICCs 0.93 and 0.90 between the BrainAGE scores calculated from two shortly delayed scans
on the same MRI scanner and on di↵erent 1.5T and 3.0T scanners, respectively, the BrainAGE
framework proved its ability to provide reliable estimates.
The sample-specific o↵sets that emerged in the estimation of BrainAGE scores seem to
depend on the kind of MRI scanner used, its field-strength, the scanning sequences, and other
sample-specific parameters. Therefore, the influences of varying image quality and segmentation
quality in training and test data on brain age estimation quality limit the reliability of the
proposed method and should thus be carefully controlled in future studies as well as analyzed
further within even larger samples. But since these o↵sets proved to be systematic in all subjects
within the same sample, it can be easily controlled for by a linear shift. When quantifying brain
aging and comparing BrainAGE in di↵erent clinical samples, one should include samples of
healthy subjects in order to control for potential sample- and/or MRI scanner-specific o↵sets in
the estimated scores. There is no need to include control subjects to correct for potential o↵sets
when examining only the relation between BrainAGE and other measures or the di↵erence
between brain aging in two subsamples of the same sample. Here, the BrainAGE framework is
robust and can furthermore be applied to and generalized across di↵erent scanners. These results
are in line with Klo¨ppel et al. (2008b), indicating that the e↵ect of the scanner is su ciently
di↵erent from that of aging processes.
Regarding the relevance within the clinical context, the BrainAGE approach again proved
its potential to indicate accelerated brain aging based on structural MRI data. Subjects with
AD and subjects with MCI who converted to AD and cognitively declined within 3 years of
follow-up (pMCI) exhibited significantly larger baseline BrainAGE scores compared to control
subjects and those with MCI who remained cognitively stable (sMCI). Further, the BrainAGE
framework even proved its capability of recognizing accelerated brain atrophy in a longitudinal
design. Already starting with a higher baseline BrainAGE score of about 6 to 7 years in pMCI
and AD, brain aging accelerates even more during follow-up, at the speed of 1 additional year in
brain atrophy per follow-up year in pMCI subjects and 1.5 additional years in brain atrophy per
follow-up year in AD patients. This accumulated to a mean BrainAGE score of about 9 years at
the last scan in both groups, with mean follow-up durations of 2.6 years for pMCI and 1.7 years
for AD. Compared to that, sMCI and healthy control subjects did not show any deviations
from healthy brain aging at baseline or at follow-up. These results are in line with recent studies
that showed increased GM atrophy of approximately 2% per year in AD (Anderson et al., 2012),
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accelerated changes in whole brain volume in MCI (Driscoll et al., 2009), acceleration in atrophy
rates as subjects progress from MCI to AD (Jack et al., 2008), and greater GM loss in certain
regions in pMCI subjects (Che´telat et al., 2005; Desikan et al., 2008; Leow et al., 2009; McDonald
et al., 2012; Sluimer et al., 2009). Furthermore, our results also support the assumption of AD
being a form of or at least being associated with accelerated aging (Cao et al., 2010; Driscoll
et al., 2009; Dukart et al., 2011; Jones et al., 2011; Saetre et al., 2011; Spulber et al., 2010).
Additionally, the individual BrainAGE scores were clearly related to measures of severity
of clinical disease, most pronounced in subjects already diagnosed as AD, as well as cognitive
functioning, most pronounced in MCI subjects converting to AD within the next 3 years. Even
more interestingly and clinically valuable, the BrainAGE scores estimated at baseline were
already moderately correlated to the prospective worsening of cognitive functioning within the
next 3 years. Cognitive decline was recently found to progressively accelerate years before being
diagnosed as AD (Wilson et al., 2011), and be correlated with the atrophy rates in specified
brain regions (Desikan et al., 2008). Our results support the suggested relationship between
progressive acceleration in brain aging and rate of change in cognitive functioning as well as
clinical severity in pMCI and AD during follow-up. Furthermore, we could even show a distinct
pattern of accelerated brain aging in pMCI subjects being more closely related to the worsening
of higher cognitive functions, but slightly less with disease severity, whereas in AD patients
accelerated brain aging was more closely related to disease severity and slightly less with the
worsening of higher cognitive functions. Regarding NO and sMCI subjects, a ceiling e↵ect was
observed as well as a slightly lower variance within the cognitive scores. This may be mainly
due to the fact that the scales analyzed in this study were used specifically to identify clinical
disease severity as well as deterioration in cognitive functioning in the ADNI sample. Future
work should further explore the relationship between BrainAGE and cognitive functioning with
cognitive scales that are more appropriate to capture healthy cognitive aging.
In conclusion, the BrainAGE framework demonstrated its potential to reliably indicate ac-
celerated brain aging. Since an additional increase in BrainAGE scores as well as profound
relationships to disease severity and prospective worsening of cognitive functions were found in
pMCI and AD during follow-up, the validity of individual BrainAGE scores indicating acceler-
ated brain aging is further strengthened. Future work should demonstrate the applicability of
the BrainAGE method on a single subject level in order to indicate early on those people at
risk for converting to AD. Recently, we already demonstrated the capability of the BrainAGE
approach to work on a single subject level by classifying subjects as either children (age range
5 – 10 years) or adolescents (age range 13 – 18 years), based on their estimated brain age, with
97% accuracy (sensitivity = 98%, specificity = 96%; Franke et al., 2012b).
The implication of these results is that this approach could potentially lead to improved
identification of people at risk of faster degradation of brain structure and function and po-
tential risk for AD, thus contributing to an early diagnosis of neurodegenerative diseases, and
facilitate early treatment or a preventative intervention. Depending on the availability of sub-
ject data, future explorations could include applying this approach to several risk factors for
accelerated brain aging and dementia, like diabetes (de Bresser et al., 2010; van Elderen et al.,
2010), the metabolic syndrome (Solfrizzi et al., 2011), or other lifestyle factors (Chen et al.,
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2009; Clarke, 2006; Scarmeas et al., 2009; Solfrizzi et al., 2008), to predict the severity of clinical
symptoms or the rate of cognitive decline, to di↵erentiate between di↵erent kinds of dementia
(e.g., fronto-temporal dementia), and to evaluate the therapeutic e↵ect of drugs or other treat-
ment modalities. Additionally, since individual quality of life is increasingly being suggested as
a crucial outcome variable for health-improving and preventive interventions in old age (Garratt
et al., 2002; Martin et al., 2012), it may be enlightening to integrate the BrainAGE approach
into the recently presented “functional quality of life” (fQOL) model (Martin et al., 2012). This
model determines the quality of life with a dynamic approach, allowing the testing of the com-
plex relations between individual functionality judgments (e.g., individual resources, activities,
central life domains) and how these relations can be adapted to stabilize or increase individual
fQOL. Moreover, the fQOL can be applied to compare between and within subjects across the
lifespan. Hence, future work may examine the functional value of individual BrainAGE scores
and its complex interactions with fQOL-determining variables such as subjective representa-
tions as well as evaluations of cognitive performance (e.g., memory) in order to finally determine
individuals’ overall quality of life.
Consequently, in the future this novel BrainAGE approach may prove clinically valuable in
detecting both normal and abnormal brain aging, providing important prognostic information.
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4.1 Abstract
Aging alters brain structure and function and diabetes mellitus (DM) may accelerate this pro-
cess. This study investigated the e↵ects of type 2 DM on individual brain aging as well as the
relationships between individual brain aging, risk factors and functional measures. To di↵er-
entiate a pattern of brain atrophy that deviates from normal brain aging, we used the novel
BrainAGE approach, which determines the complex multidimensional aging pattern within the
whole brain by applying established kernel regression methods to anatomical brain MRIs. The
“Brain Age Gap Estimation” (BrainAGE) score was then calculated as the di↵erence between
chronological age and estimated brain age. 185 subjects (98 with type 2 DM) completed an MRI
at 3.0T, laboratory and clinical assessments. Twenty-five subjects (12 with type 2 DM) also
completed a follow-up visit after 3.8 ± 1.5 years.
The estimated brain age of DM subjects was 4.6 ± 7.2 years greater than their chronological
age (p = 0.0001), whereas within the control group, estimated brain age was similar to chrono-
logical age. As compared to baseline, the average BrainAGE scores of DM subjects increased by
0.2 years per follow-up year (p = 0.034), whereas the BrainAGE scores of controls did not change
between baseline and follow-up. At baseline, across all subjects, higher BrainAGE scores were
associated with greater smoking and alcohol consumption, higher tumor necrosis factor alpha
(TNF↵) levels, lower verbal fluency scores and more severe depression. Within the DM group,
higher BrainAGE scores were associated with longer diabetes duration (r = 0.31, p = 0.019)
and increased fasting blood glucose levels (r = 0.34, p = 0.025).
In conclusion, type 2 DM is independently associated with structural changes in the brain
that reflect advanced aging. The BrainAGE approach may thus serve as a clinically relevant
biomarker for the detection of abnormal patterns of brain aging associated with type 2 DM.
4.2 Introduction
The global prevalence of type 2 diabetes mellitus (DM) is projected to rise sharply over the
coming decades. Individuals aged 65 years and older have a particularly high risk of developing
diabetes complications, due to the combination of both modifiable (i.e., lifestyle) and non-
modifiable risk factors (Zimmet et al., 2001). Within this population, type 2 DM has been
linked to increased brain atrophy (Araki et al., 1994; de Bresser et al., 2010; Last et al., 2007;
Novak et al., 2011; Schmidt et al., 2004; van Elderen et al., 2010), impaired cognitive function
(Reijmer et al., 2011) and increased risk of depression (Ali et al., 2006; Anderson et al., 2001)
and dementia, including both vascular dementia and Alzheimer’s disease (AD; Biessels et al.,
2006; Cheng et al., 2012; Janson et al., 2004; Tan et al., 2011; Velayudhan et al., 2010; Xu et al.,
2004).
Chronic hyperglycemia is associated with vascular disease and neurotoxicity leading to neu-
ronal damage (Tomlinson and Gardiner, 2008). Within the brain, hyperglycemia appears to
induce structural abnormalities resembling the progressive, widespread atrophy often associated
with biological aging (Biessels et al., 2006; Gispen and Biessels, 2000). Moreover, within the
DM population, such generalized atrophy may be detected at an earlier age (Araki et al., 1994).
Clinical manifestations of DM-related brain abnormalities include worse functional status (Bies-
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sels et al., 2006; Stewart and Liolitsa, 1999), deficits in cognition (i.e., verbal memory, mental
flexibility, and processing speed; Cheng et al., 2012; Gispen and Biessels, 2000), and depres-
sion (Heuser, 2002; Katon et al., 2012; Wolkowitz et al., 2010, 2011). As such, recognition and
quantification of subtle deviations from aging-related brain atrophy may a↵ord prospective iden-
tification and subsequent treatment of patients with DM who are at risk for clinically-significant
functional decline.
Based on the widespread but well-ordered brain tissue loss that occurs with healthy aging
into senescence (Good et al., 2001), we previously proposed a modeling approach to identify
abnormal aging-related brain atrophy that may precede the onset of clinical symptoms. We
introduced a novel BrainAGE approach (Franke et al., 2010, 2012b) based on a database of single
time-point structural magnetic resonance imaging (MRI) data that aggregates the complex,
multidimensional aging patterns across the whole brain to one single value, i.e. the estimated
brain age (Figure 1.4A, page 13). Consequently, subtle deviations in “normal” brain atrophy can
be directly quantified in terms of years by analyzing only one standard MRI scan per subject
(Figure 1.4B, page 13). Recently, we demonstrated that the BrainAGE approach enables the
identification of advanced brain aging in subjects with mild cognitive impairment and AD, and
observed profound relationships between BrainAGE, disease severity, prospective worsening of
cognitive functions (Franke et al., 2012a), conversion to AD (Gaser et al., 2013), as well as
certain health and lifestyle markers (e.g., the metabolic syndrome; Franke et al., 2013b).
In this study, we implemented the BrainAGE method to quantify the e↵ects of type 2 DM on
individual brain aging in non-demented older adults. We further explored the relationships be-
tween individual brain aging and clinically significant lifestyle risk factors (i.e., smoking duration,
alcohol intake), clinical laboratory data (i.e., fasting blood glucose level as a potential indicator
of hyperglycemia, tumor necrosis factor alpha (TNF↵) as a potential indicator of persistent in-
flammation), and common clinical outcomes (i.e., cognition, depression). We hypothesized that
type 2 DM is associated with greater BrainAGE scores, and that clinically significant risk factors
additionally contribute to this process. We also hypothesized that those individuals with greater
BrainAGE scores would also exhibit worse outcomes related to cognition and depression.
4.3 Research design and methods
4.3.1 Subjects
To train the age estimation framework, we used MRI data of 561 healthy subjects (250 male) from
the publicly accessible IXI cohort (http://www.brain-development.org; data downloaded in
September 2011) aged 20 – 86 years (mean (SD) = 48.6 (16.5) years; for more sample details
see Franke et al., 2010).
The current BrainAGE analyses were conducted using existing records of 185 subjects (98
with diagnosed type 2 DM; Table 4.1). who previously participated in studies within the Syn-
cope and Falls in the Elderly (SAFE) Laboratory at the Beth Israel Deaconess Medical Center
(BIDMC). A subset of these subjects (n = 25, 12 with type 2 DM; Table 4.2) also completed a
follow-up MR scan after an average of 3.8 years (SD = 1.5).
CHAPTER 4. ADVANCED BRAIN AGING IN DIABETES 54
Table 4.1: Demographic and clinical variables of the cross-sectional control and type 2 DM groups.
Non-diabetic control group Type 2 DM group p
No. subjects 87 98 n.s.
Males/Females 41/46 53/45 n.s.
Age mean (years) 65.3 (8.5) 64.6 (8.1) n.s.
Hypertension (yes/no) 22/65 56/42 ⇤
Diabetes duration (years) – 11.3 (9.3) –
GM volume (ml) 528.9 (63.5) 519.0 (52.3) n.s.
WM volume (ml) 540.2 (78.3) 536.2 (90.8) n.s.
Total brain volume (ml) 1347.7 (147.2) 1338.1 (146.2) n.s.
BMI (kg/m2) 25.4 (3.7) 28.8 (4.8) ⇤⇤⇤
Smoking duration (years) 9.4 (15.1) 10.9 (14.6) n.s.
Alcohol intake (dose/week) 2.0 (3.3) 5.1 (14.3) n.s.
Non-fasting blood glucose (mg/dL) 82.0 (13.2) 124.0 (56.4) ⇤⇤⇤
Fasting blood glucose (Visit 2) 86.7 (13.6) 110.6 (32.4) n.s.
TNF↵ (pg/mL) 1.6 (0.7) 1.6 (0.5) n.s.
Verbal fluency (T-score) 50.0 (10.1) 39.5 (12.8) ⇤⇤⇤
Geriatric Depression Scale (total score) 3.8 (4.8) 6.4 (6.4) n.s.
[Notes: Data are means ± (SD) unless otherwise indicated. p denotes between-group comparisons. ⇤p < 0.05, ⇤⇤⇤p < 0.001.]
Table 4.2: Demographic and clinical variables of the longitudinal subsample.
Non-diabetic control group Type 2 DM group p
No. subjects 13 12 n.s.
Males/Females 5/8 4/8 n.s.
Hypertension (yes/no) 2/11 7/5 n.s.
Baseline Age mean (years) 69.9 (5.5) 63.3 (6.9) ⇤
GM volume (ml) 501.6 (62.5) 439.1 (47.4) n.s.
WM volume (ml) 528.7 (84.1) 554.5 (76.6) n.s.
Total brain volume (ml) 1308.1 (143.9) 1302.0 (150.8) n.s.
Follow-up Age mean (years) 73.9 (5.7) 66.8 (6.7) ⇤⇤
GM volume (ml) 511.7 (63.6) 505.1 (47.7) n.s.
WM volume (ml) 522.9 (65.0) 533.7 (108.8) n.s.
Total brain volume (ml) 1306.3 (127.6) 1303.5 (161.8) n.s.
[Notes: Data are means ± (SD) unless otherwise indicated. p denotes between-group comparisons. ⇤p < 0.05, ⇤⇤p < 0.01.]
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Participants were recruited consecutively via advertisement in the local community and pro-
vided informed consent as approved by the Institutional Review Board. Controls were required
to have normal fasting glucose, but had a similar distribution of risk factors. All participants
were screened with a medical history and physical and laboratory examinations. Participants
with DM were treated with insulin, oral glucose-control agents (sulfonylurea, second generation
agents or their combinations), or diet only. Several participants in each group were treated for
hypertension and/or hypercholesterolemia. Excluded were participants with type 1 DM, a his-
tory of stroke, myocardial infarction within 6 months, and other clinically important cardiac
diseases, arrhythmias, significant nephropathy, kidney or liver transplant, renal or congestive
heart failure, carotid artery stenosis (over 50% by medical history and MR angiography), neuro-
logical or other systemic disorders; claustrophobia, metal implants, pacemakers, arterial stents
incompatible with MRI. All participants were admitted to the Clinical Research Center for an
overnight stay. Laboratory chemistries were collected after overnight fasting, and MRI was done
before noon. Functional clinical outcomes were acquired through a battery of neuropsychological
tests, including assessments for learning and memory, depression, and physical function.
In order to quantify the relationship between BrainAGE scores, life-style risk factors and
clinical outcomes, the following data were extracted: body mass index (BMI), smoking duration,
alcohol intake, non-fasting blood glucose levels, parameters of diabetes control (duration, fasting
blood glucose levels), common clinical outcomes (i.e., verbal fluency, more specifically ‘semantic
fluency’, requiring the generation of exemplars of the category ‘animals’; Harrison et al., 2000;
Fisher et al., 2004) and depression as measured with the Geriatric Depression Scale (GDS;
Yesavage, 1988), and inflammation markers (TNF↵).
4.3.2 Magnetic resonance imaging
All studies were performed within the Center for Advanced MR Imaging at the BIDMC on
the same 3.0 Tesla GE HDx MRI scanner using a quadrature and phase array head coils (GE
Medical Systems, Milwaukee, WI). Anatomical images were acquired using 3-D magnetization
prepared rapid gradient echo (MP-RAGE) (TR/TE/TI = 7.8/3.1/600 ms, 3.0 mm slice thickness,
52 slices, bandwidth = 122 Hz per pixel, flip angle = 10 , 24 cm x 24 cm FOV, 256 x 192 matrix
size) and fluid attenuated inversion recovery (FLAIR) (TR/TE/TI = 11000/161/2250 ms, 5 mm
slice thickness, 30 slices, bandwidth = 122 Hz per pixel, flip angle = 90 , 24 cm x 24 cm FOV,
256 x 160 matrix size) sequences.
4.3.3 Preprocessing of MRI data and data reduction
Preprocessing of the T1-weighted images was done using the SPM8 package (http://www.fil.
ion.ucl.ac.uk/spm) and the VBM8 toolbox (http://dbm.neuro.uni-jena.de), running un-
der Matlab. All T1-weighted images were corrected for bias-field inhomogeneities, then spa-
tially normalized and segmented into gray matter (GM), white matter (WM), and cerebrospinal
fluid (CSF) within the same generative model (Ashburner and Friston, 2005). The segmenta-
tion procedure was extended by accounting for partial volume e↵ects (Tohka et al., 2004), by
applying adaptive maximum a posteriori estimations (Rajapakse et al., 1997), and by using a
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hidden Markov random field model (Cuadra et al., 2005; Gaser, 2009). The images were pro-
cessed with a ne registration and smoothed with 8-mm full-width-at-half-maximum smoothing
kernels. Spatial resolution was set to 8 mm. For further data reduction, principal component
analysis (PCA) was performed on the training sample with subsequently applying the estimated
transformation parameters to the test sample. PCA was done using the “Matlab Toolbox for
Dimensionality Reduction” (http://ict.ewi.tudelft.nl/~lvandermaaten/Home.html), run-
ning under Matlab.
4.3.4 Age estimation framework
The BrainAGE framework utilizes a machine-learning pattern recognition method, namely rel-
evance vector regression (RVR; Tipping, 2001). It was recently developed to estimate individual
brain ages based on T1-weighted images (Franke et al., 2010). In general, the model is trained
with preprocessed whole brain structural MRI data of the training sample (here: the IXI sam-
ple). Subsequently, the brain age of each test subject can be estimated using the individual
tissue-classified MRI data, aggregating the complex, multidimensional aging pattern across the
whole brain into one single value (Figure 1.4A, page 13). The di↵erence between estimated and
true chronological age will reveal the individual “Brain Age Gap Estimation” (BrainAGE) score.
Consequently, the BrainAGE score directly quantifies the amount of acceleration or deceleration
of brain aging. For example, if a 70 years old individual has a BrainAGE score of +5 years,
this means that this individual shows the typical atrophy pattern of a 75 year old individual
(Figure 1.4B, page 13). Recent work has demonstrated that this method provides reliable and
stable estimates (Franke et al., 2012a). Specifically, the BrainAGE scores calculated from two
shortly delayed scans on the same MRI scanner, as well as on separate 1.5T and 3.0T scanners,
produced intraclass correlation coe cients (ICC) of 0.93 and 0.90, respectively.
Within this study, the BrainAGE framework was applied using the linear combination of
preprocessed (as described in the section 4.3.3) GM and WM images. For training the model
as well as for predicting individual brain ages, we used “The Spider” (http://www.kyb.mpg.
de/bs/people/spider/main.html), a freely available toolbox running under Matlab. For an
illustration of the most important features (i.e., the importance of voxel locations for regression
with age) that were used by the RVR to model normal brain aging and more detailed information
please refer to Figure 2.5, page 27.
4.3.5 Statistical analysis
Descriptive statistics were used to summarize all variables. Demographic and laboratory data
were compared between the control and the DM groups using analysis of variance (ANOVA) for
continuous variables or Kruskal-Wallis tests for categorical variables and variables that were not
normally distributed. Normality was tested using Shapiro-Wilk tests. Cross-sectionally, within-
group di↵erences between estimated brain age and biological age were tested using Student’s
t-test.
The e↵ect of DM on BrainAGE was determined with ANOVA. The dependent variable was
the BrainAGE score. Model e↵ects included group (i.e., DM & non-DM controls), hypertension
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(i.e., with/without hypertension) and gender.
Relationships between BrainAGE and clinical parameters were then analyzed in the whole
sample (i.e., DM and non-DM subjects together), controlling for age, gender, and diabetes dura-
tion (with diabetes duration = 0 years for non-DM controls). As not all subjects had values for
all clinical variables, univariate correlation analyses were used (instead of multivariate models) to
assess the relationship between BrainAGE and distinguished lifestyle measures (i.e. BMI, smok-
ing duration, alcohol intake), clinical laboratory data (i.e. fasting blood glucose level, TNF↵),
and functional measures (i.e. T-score for verbal fluency, total GDS score for depression). In or-
der to control for covariates, Pearson’s pairwise correlation were used for normally distributed
variables, and Spearman’s correlations were used for variables that are not normally distributed,
with adjustment for age, gender and diabetes duration (right-tailed for verbal fluency, left-tailed
for all others). To control for multiple comparisons, Bonferroni-Holm correction (Holm, 1979)
was applied, adjusting the p-value for the number of variables analyzed (i.e., 7).
The e↵ect of diabetes-status within the relationships between BrainAGE and lifestyle param-
eters, clinical laboratory data and outcome measures were investigated by performing analysis of
covariance (ANCOVA). Each specific ANCOVA included all those subjects who were measured
in each specific clinical variable, sub-grouped by DM. Since fasting blood glucose levels were
provided for only three non-DM control subjects, this variable was excluded from this analy-
sis. For all other variables, the model fitted separate lines for both groups, thus allowing the
intercept as well as the slopes to vary between both groups.
To further explore the relationship between BrainAGE and clinical parameters, the whole
sample was divided into quartiles for each of the significantly related lifestyle measures (i.e. smok-
ing duration, alcohol intake), clinical laboratory data (i.e. fasting blood glucose level, TNF↵),
and outcome measures (i.e. verbal fluency, depression). To illustrate the relationships between
individual brain aging and extreme levels in each of these variables, the BrainAGE scores in the
1st quartile (lowest 25% of values) of each lifestyle and functionality measure were tested against
the BrainAGE scores in 4th quartile (highest 25% of values) of each lifestyle and functionality
measure, using one-tailed t-tests (right-tailed for verbal fluency, left-tailed for all others). Similar,
Bonferroni-Holm-adjusted p-values were used to determine significance. Within the subsample
that completed two MRI scans, the longitudinal changes in individual BrainAGE scores were
fitted against time between both scans with a multivariate linear regression model. BrainAGE
scores at baseline and follow-up visit, as well as longitudinal changes in BrainAGE were com-
pared between both groups using ANOVA.
The Shapiro-Wilk test was performed using JMP 9.0 (www.jmp.com). All other testing was
performed using Matlab 7.11. (www.mathworks.com).
4.4 Results
4.4.1 Group Characteristics
All variables except diabetes duration, BMI, alcohol intake and GDS scores were normally
distributed. Age, gender, GM, WM and total brain volumes did not di↵er between groups
(Table 4.1). The DM group had higher BMI (p < 0.0001), higher non-fasting blood glucose
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Figure 4.1: Estimated brain age vs. chronological age for controls and subjects with type 2
DM. The BrainAGE scores (i.e., the di↵erence between the estimated and the chronological age) di↵ered
between groups, with mean (± SD) BrainAGE scores of 0.0 ± 6.7 years in healthy controls (blue) and
4.6 ± 7.2 years in type 2 DM subjects (red; p < 0.0001). [Figure and legend from Franke et al. 2013a.]
levels (p < 0.0001), greater prevalence of hypertension (p < 0.05), and worse performance in
verbal fluency (p < 0.0001) than controls (Table 4.1).
4.4.2 Cross-sectional BrainAGE analyses
Although brain volumes did not di↵er between the groups, the DM subjects had significantly
higher BrainAGE scores than controls (F = 17.2, p = 0.0001; Figure 4.1). Additionally,
BrainAGE scores did not correlate to brain volumes (Figure 4.2). Within the control group,
estimated brain age was similar to chronological age (t(0.975,86) = 0.0, p = 1.0). In DM sub-
jects, however, the average BrainAGE score was 4.6 years (SD = 7.2years); i.e., their estimated
brain age was 4.6 years greater than their chronological age (t(0.975,97) = 6.4, p = 0.0001). Ad-
ditionally, within the DM group, those with longer diabetes duration had higher BrainAGE
scores (r = 0.31, p = 0.019). This relationship was independent of age, gender, and duration of
hypertension history.
Across all subjects, BrainAGE scores were higher in males as compared to females (F = 7.7,
p = 0.006). There were no e↵ects for hypertension (F = 0.0, p = 0.9), or any interaction (group
⇤ hypertension: F = 0.6, p = 0.46; group ⇤ gender: F = 0.7, p = 0.41; hypertension ⇤ gender:
F = 0.1, p = 0.79).
Across all subjects, higher BrainAGE scores were significantly correlated with lifestyle fac-
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tors, i.e. increased duration of smoking (r = 0.20, p = 0.007) and greater alcohol consumption
(r = 0.24, p = 0.001), as well as clinical laboratory data, i.e. higher fasting blood glucose
(r = 0.34, p = 0.025) and TNF↵ (r = 0.29, p = 0.01) levels. Higher BrainAGE scores were
also correlated with lower verbal fluency (r =  0.25, p = 0.006) and higher depression scores
(r = 0.23, p = 0.012). All correlations were independent of age, gender, and diabetes duration.
Additionally, ANCOVAs were performed to investigate the e↵ects of DM status on the re-
lationships between BrainAGE scores and distinguished lifestyle factors, clinical variables, and
outcome measures. Although BrainAGE scores were generally higher in DM subjects, higher
BrainAGE scores were also related to increased smoking duration (F = 5.13, p < 0.05), in-
creased alcohol intake (F = 7.63, p < 0.01), increased TNF↵ (F = 6.24, p < 0.05), decreased
verbal fluency (F = 4.07, p < 0.05), and increased GDS scores (F = 7.17, p < 0.01) in DM
Figure 4.2: BrainAGE scores plotted against GM and WM volumes for all subjects.
BrainAGE scores did not correlate to either GM (top; r = 0.02, p = 0.81) or WM volumes (bottom;
r = 0.09, p = 0.20). [Figure and legend from Franke et al. 2013a.]
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Table 4.3: ANCOVA results for BrainAGE scores and distinguished variables.
Model Coe cient estimates
Group
Variable Group x
Intercept Slope
value Value
F p F p F p t p t p
BMI 17.4 0.0001 0.02 0.89 2.4 0.12 0.94 0.35 0.36 0.39
Smoking duration 21.4 0.0001 5.13 0.02 0.0 0.97 2.6 0.01 2.26 0.02
Alcohol intake 11.8 0.0007 7.63 0.006 6.82 0.009 2.13 0.03 3.54 0.0005
TNF↵ 11.2 0.001 6.24 0.01 0.16 0.69 1.61 0.11 2.18 0.03
Verbal fluency 6.28 0.01 4.07 0.04 0.06 0.80 2.79 0.006 1.96 0.05
Geriatric Depression Scale (GDS) 7.12 0.009 7.17 0.008 1.46 0.23 1.47 0.14 2.94 0.004
[Notes: Bold type = significant test results.]
Table 4.4: Comparison of BrainAGE scores between the quartile groups in the whole sample.
Mean (SD) BrainAGE score (years)
p for trend
1st quartile 2nd quartile 3rd quartile 4th quartile
BMI 3.04 (6.06) 0.59 (7.54) 1.68 (5.75) 3.90 (7.37) 0.29
Smoking duration 1.67 (6.43) – 0.87 (6.51) 5.07 (7.25) 0.012
Alcohol intake 1.30 (6.57) – 0.82 (5.97) 5.42 (6.07) 0.002
Fasting blood glucose 2.38 (7.34) 0.13 (7.67) 5.21 (4.22) 7.85 (3.02) 0.036
TNF↵  1.30 (6.31) 0.20 (6.64) 0.51 (7.16) 4.11 (5.75) 0.10
Verbal fluency 6.47 (6.98) 3.14 (6.92) 0.72 (5.38) 0.86 (6.63) 0.002
Geriatric Depression Scale (GDS) 0.62 (6.56) 2.78 (7.65) 2.72 (5.37) 6.01 (5.73) 0.015
[Notes: Bold type = significant test results.]
subjects as well as in non-DM controls (Table 4.3, Figure 4.3).
To exemplarily quantify the relationship between brain atrophy and lifestyle factors, clinical
laboratory data and functionality, the BrainAGE scores of subjects with the lowest values in
those measures (i.e., 1st quartile) versus subjects with the highest values in those measures
(i.e., 4th quartile) were contrasted (Table 4.4, Figure 4.4). These analyses resulted in significant
di↵erences in BrainAGE of 3.4 years for smoking duration (p = 0.004), 4.1 years for alcohol
intake (p = 0.003), 5.5 years for fasting blood glucose (p = 0.02), 5.4 years for TNF↵ (p = 0.006),
5.6 years for verbal fluency (p = 0.001), and 5.4 years for depression scores (p = 0.002).
4.4.3 Longitudinal BrainAGE analyses
A subsample of 25 subjects (12 DM subjects and 13 controls) completed a second MRI scan
3.8 ± 1.5 years after their baseline assessment. In this subsample, GM, WM as well as total brain
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Figure 4.3: ANCOVA plots for BrainAGE scores and distinguished variables. BrainAGE
scores are plotted against BMI, smoking duration, alcohol intake, TNF↵, verbal fluency, and GDS scores
for non-DM controls (blue) and subjects with type 2 DM (red). In both groups, higher BrainAGE scores
were significantly related to increased smoking duration (p < 0.05), increased alcohol intake (p < 0.01),
increased TNF↵ (p < 0.05), decreased verbal fluency (p < 0.05), and increased GDS scores (p < 0.01).
[Figure and legend from Franke et al. 2013a.]
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Figure 4.4: Exemplary quartile analyses. Mean BrainAGE scores in subjects with values in the
1st and 4th quartiles of distinguished variables. Error bars depict the standard error of the mean (SEM).
[Figure and legend from Franke et al. 2013a.]
volumes did not di↵er between groups (Table 4.2), or across time points (GM volume: p = 0.48;
WM volume: p = 0.58; total brain volume: p = 0.99). Interestingly, however, we observed a
change in BrainAGE over time that was dependent upon group (F = 6.9, p = 0.015; Figure
4.5). Specifically, as compared to baseline, average BrainAGE scores increased in DM subjects
by 0.2 years per follow-up year. Within the control group, as expected, BrainAGE scores were
similar to chronological age at baseline and follow-up and therefore did not change over time.
In other words, whereas the BrainAGE scores of patients with DM were on average 5.1 years
higher than controls at baseline (F = 6.2, p = 0.020), they were on average 5.9 years higher
than controls at follow-up (F = 5.0, p = 0.034).
4.5 Discussion
This study implemented a novel MRI-based biomarker that comprises well-established and fully
automated steps for processing standard T1-weighted MR images, aggregating the complex,
multidimensional aging pattern across the whole brain into one single value; i.e. the BrainAGE
score. This method has the advantage of accurately and reliably estimating brain age with
minimal preprocessing and parameter optimization (Franke et al., 2010, 2012b), using a single
anatomical scan. The BrainAGE score directly quantifies subtle deviations from the normal
brain-aging pattern and may therefore provide clinically important prognostic information.
In this study, the BrainAGE approach was used to determine the e↵ects of type 2 DM
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Figure 4.5: Longitudinal BrainAGE changes in controls and type 2 DM subjects. Longitudinal
changes in BrainAGE scores for non-DM control subjects (blue) and type 2 DM subjects (red). Thin
lines represent individual changes in BrainAGE over time; thick lines indicate estimated average changes
for each group. The change in BrainAGE over time was dependent upon group (p = 0.01), providing
preliminary longitudinal evidence that type 2 DM accelerates brain aging. [Figure and legend from Franke
et al. 2013a.]
on brain aging. Although GM, WM and total brain volumes did not di↵er between groups,
BrainAGE scores were on average 4.6 years greater in DM subjects as compared to non-DM
controls. Moreover, BrainAGE scores tended to be higher in those with longer diabetes duration
and higher fasting blood glucose levels, suggesting a potential link between worse glycemic
control and pathologic brain atrophy. Longitudinal analyses further indicated that DM might
result in greater increases in BrainAGE scores over time (despite no detectable change in global
brain tissue volumetrics). Together, these results suggest that the BrainAGE score may be
sensitive to subtle, glucose-mediated structural brain changes that reflect a pattern of premature
brain aging (Araki et al., 1994; Biessels et al., 2006; Gispen and Biessels, 2000; van Elderen et al.,
2010; Velayudhan et al., 2010; Tan et al., 2011).
This study also revealed that individual brain aging was correlated with numerous clinical
outcomes. Across all subjects, and independently of diabetes duration, age and gender, those
with higher BrainAGE scores consumed more alcohol. This observation is supported by recent
studies suggesting a U-shaped relationship between alcohol consumption and cognitive impair-
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ment (Anttila et al., 2004; Solfrizzi et al., 2008). Higher BrainAGE scores were also linked to
increased TNF↵ levels, which are now believed to play a central role in the pathogenesis of AD
(Tobinick and Gross, 2008). To this end, those with higher BrainAGE scores also tended to have
worse verbal fluency. Finally, those subjects with higher BrainAGE scores were more likely to
have more severe depressive symptoms, which is in line with recent studies linking depression
to both advanced brain aging (Heuser, 2002; Wolkowitz et al., 2010, 2011) as increased risk of
dementia (Katon et al., 2012).
The BrainAGE approach was designed to recognize and indicate deviations in age-related
spatiotemporal brain changes. Subjects with a high BrainAGE score may thus be at risk for
several neurodegenerative diseases and related functional declines. Higher BrainAGE scores as
well as profound correlations to disease severity and prospective worsening of cognitive func-
tions have already been observed in subjects with mild cognitive impairment and AD (Franke
et al., 2012a). The BrainAGE approach was even capable of identifying subjects who will be
diagnosed with AD up to three years in advance, with each additional year in the BrainAGE
score being associated with a 10% greater risk of developing AD (Gaser et al., 2013). As such,
larger prospective trials are warranted to confirm our initial observation that type 2 DM leads
to premature brain aging, and to determine whether this pattern is similar to those of other
neuodegenerative diseases. In future research, we aim to further explore and disentangle age- and
unrelated disease-based processes of brain atrophy in neurodegenerative diseases (e.g. vascular
dementia, AD) as well as its e↵ects on BrainAGE estimations.
In the present study, there was considerable variance associated with individual BrainAGE
scores, as well as intra-individual changes in BrainAGE scores over time. As we have previously
reported (Franke et al., 2013b), and confirmed in this study, a number of nutrition, lifestyle, and
health parameters likely contribute to this variance. For example, in older male adults without
major disease, 39% of the inter-subject variance in BrainAGE was explained by the set of clinical
markers under consideration, with markers of the metabolic syndrome mainly contributing to
this variance (Franke et al., 2013b). As individual changes in lifestyle (e.g., smoking cessation,
physical activity, intake of unsaturated fatty acids, moderate alcohol intake) were shown to lower
the risk of cognitive decline and dementia (Erickson et al., 2010; Frisardi et al., 2010; Nepal
et al., 2010), such lifestyle changes may be also related to a decrease in individual BrainAGE.
Future research is therefore warranted to determine the e↵ects of individual health and lifestyle
modification, as well as improved DM control (e.g., a lowering of blood glucose levels), on
longitudinal changes in individual BrainAGE scores.
It is of note that white matter lesions, which occur primarily due to cerebro-vascular diseases
(Hadjidemetriou et al., 2008; Zhan et al., 2009), are not detected in the segmentation approach
used within the BrainAGE analysis. Such lesions segmented as GM may therefore influence the
relevance vector regression. However, as the prevalence of white matter lesions was minimal in
the current cohort, it is unlikely that this limitation influenced the training of “normal brain
aging”. Thus, even though the current BrainAGE method has high test-retest reliability (Franke
et al., 2012a), it may benefit from the development and implementation of segmentation methods
that enable automated detection of white matter lesions even without any additional FLAIR
sequence (Klo¨ppel et al., 2011).
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As not all subjects had values for all clinical variables, we were unable to utilize multivariate
models to examine the relationship between BrainAGE and health-related outcomes, as this
approach would have resulted in an extreme reduction in sample size (n = 17). Future studies
with larger samples are therefore needed to enable multivariate analyses designed to identify the
complex interactions between brain aging, lifestyle factors and clinical outcomes. Moreover, as
our prospective cohort was rather small, it still remains unclear whether the presence of type
2 DM and/or lifestyle risk factors represents the cause or consequence of observed associations.
Further research is therefore needed to extend our results on the longitudinal relationships
between individual brain aging and miscellaneous risk factors (e.g., diabetes, lifestyle, depression)
in a larger population-based sample. Furthermore, the relationship between the duration of
exposure to risk factors and accelerated brain aging, and whether reversal of modifiable factors
might decelerate the progression of brain aging, should be explored.
As BrainAGE scores are calculated from a single T1-weighted MRI per subject, using pro-
cessing techniques that can be fully automated with multi-centre data, this approach may be
easily implemented into clinical practice in order to encourage the identification of subtle, yet
clinically-significant, changes in brain structure. With regards to type 2 DM, the implications of
this study may lead to a clinical tool that identifies people at risk of faster degradation of brain
structure and function and potential risk for dementias, thus contributing to an early diagnosis
of neurodegenerative diseases and facilitating early treatment or preventative interventions.
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5.1 Abstract
Alzheimer’s disease (AD), the most common form of dementia, shares many aspects of abnor-
mal brain aging. We present a novel magnetic resonance imaging (MRI)-based biomarker that
predicts the individual progression of mild cognitive impairment (MCI) to AD on the basis of
pathological brain aging patterns. By employing kernel regression methods, the expression of
normal brain-aging patterns forms the basis to estimate the brain age of a given new subject. If
the estimated age is higher than the chronological age, a positive “Brain Age Gap Estimation”
(BrainAGE) score indicates accelerated atrophy and is considered a risk factor for conversion
to AD.
Here, the BrainAGE framework was applied to predict the individual brain ages of 195 sub-
jects with MCI at baseline, of which a total of 133 developed AD during 36 months of follow-up
(corresponding to a pre-test probability of 68%). The ability of the BrainAGE framework to
correctly identify MCI-converters was compared with the performance of commonly used cog-
nitive scales, hippocampus volume, and state-of-the-art biomarkers derived from cerebrospinal
fluid (CSF). With accuracy rates of up to 81%, BrainAGE outperformed all cognitive scales
and CSF biomarkers in predicting conversion of MCI to AD within 3 years of follow-up. Each
additional year in the BrainAGE score was associated with a 10% greater risk of developing
AD (hazard rate: 1.10 [CI: 1.07 – 1.13]). Furthermore, the post-test probability was increased
to 90% when using baseline BrainAGE scores to predict conversion to AD.
The presented framework allows an accurate prediction even with multicenter data. Its fast
and fully automated nature facilitates the integration into the clinical workflow. It can be ex-
ploited as a tool for screening as well as for monitoring treatment options.
5.2 Background
The global prevalence of dementia is projected to rise sharply over the coming decades. By
2050, 1 in 85 persons worldwide will be a↵ected by Alzheimer’s disease (AD), the most common
form of dementia (Brookmeyer et al., 2007). Manifold pathological changes begin to develop
years or decades before the onset of cognitive decline (Jack et al., 2010), including premature
changes in gene expression (Cao et al., 2010; Saetre et al., 2011), accelerated age-associated
changes of the default mode network (Jones et al., 2011), and most obviously, abnormal changes
in brain structures already at the mild cognitive impairment (MCI) stage (Driscoll et al., 2009;
Spulber et al., 2010). Additionally, atrophic regions detected in AD patients were recently found
to largely overlap with those regions showing a normal age-related decline in healthy control
subjects (Dukart et al., 2011).
Early detection and quantification of abnormal brain changes is important for the prospective
identification and subsequent treatment of individuals at risk for cognitive decline and dementia.
The best validated biomarkers for an early detection include markers of brain  -amyloid-plaque
(A ) deposition, i.e. decreased cerebrospinal fluid (CSF) A 42 and positive Pittsburgh com-
pound B (PiB) amyloid imaging, as well as markers of neurodegeneration, i.e. increased CSF
tau, decreased fluorodeoxyglucose uptake on PET (FDG-PET), and structural magnetic reso-
nance imaging (MRI) measures of cerebral atrophy (Jack et al., 2010). More specifically, low
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concentrations of CSF A 42, associated with the formation of A  plaques in the brain, were
found to correlate with the clinical diagnosis of AD (Clark et al., 2003; Strozyk et al., 2003), but
not with rates of brain atrophy (Josephs et al., 2008). The process of A -plaque accumulation
begins at least 5 – 10 years (Buchhave et al., 2012) or even up to two decades before probable
manifestation of clinical symptoms and conversion to AD (Jack et al., 2009), but on its own is not
su cient to cause dementia (Aizenstein et al., 2008; Jack et al., 2010; Peskind et al., 2006; Price
and Morris, 1999; Price et al., 2009; Savva et al., 2009). At some point in the AD disease course
accelerated neurodegeneration takes place, preceding accelerated cognitive decline (Jack et al.,
2010). Although CSF tau was found to positively correlate with severity of cognitive impairment
(Buchhave et al., 2012; Shaw et al., 2009), increased CSF tau is not specific for AD but seems
to indicate neuronal injury and neurodegeneration in general (Hesse et al., 2001; Jack et al.,
2010; Schoonenboom et al., 2012). Although brain atrophy in general is not specific for AD,
MRI-detected atrophy was found to retain the closest relationship with cognitive decline (Jack
et al., 2010; Vemuri et al., 2009a,b) suggesting a crucial role for structural MRI in predicting
future conversion to AD (Frisoni et al., 2010; Jack et al., 2010).
Our recently introduced BrainAGE approach (Franke et al., 2010, 2012b) takes into account
the widespread but sequential age-related brain tissue loss. Based on single time-point structural
MRI the complex, multidimensional aging patterns across the whole brain are aggregated to
one single value, i.e. the estimated brain age (Figure 1.4A, page 13). Consequently, although
using only a standard MRI scan, the deviation in brain atrophy from normal brain aging can
be directly quantified (Figure 1.4B, page 13). We already demonstrated that the BrainAGE
approach is capable of identifying pathological brain aging in subjects with MCI and AD, and
observed profound relationships between BrainAGE, disease severity and prospective worsening
of cognitive functions (Franke et al., 2012a).
In order to explore the potential of applying the BrainAGE approach in early detection of
abnormal brain changes, this study implemented this novel MRI-based biomarker to predict
the conversion from MCI to AD within a time span of 36 months. We hypothesized that those
individuals with greater BrainAGE scores would convert to AD with worse outcomes related
to cognition and disease severity. Furthermore, a subsample of subjects with MCI, for whom
CSF data are available, will be used to compare the performance of the BrainAGE framework
in predicting conversion from MCI to AD to commonly used MRI and CSF biomarkers, which
are widely used as state-of-the-art benchmark.
5.3 Methods
5.3.1 Subjects
We utilized data obtained from the ADNI database (www.loni.ucla.edu/ADNI), including all
MCI subjects for whom baseline MRI data (1.5T), at least moderately confident diagnoses (i.e.
confidence > 2), hippocampus volumes (i.e. volumes of left and right hippocampus, calculated
by FreeSurfer Version 4.3.), and test scores in certain cognitive scales (i.e. ADAS: Alzheimer’s
Disease Assessment Scale, range 0 – 85; CDR-SB: Clinical Dementia Rating ‘sum of boxes’, range
0 – 18; MMSE: Mini-Mental State Examination, range 0 – 30) were available (data downloaded
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in May 2010). For the exact procedures of data collection and up-to-date information, see www.
adni-info.org.
Adopting the diagnostic classification at baseline and follow-up, 195 subjects were grouped
as (i) sMCI (stable MCI), if diagnosis was MCI at all available time points, but at least for
36 months (n = 62); (ii) pMCI early (progressive MCI), if diagnosis was MCI at baseline but
converted to AD within the first 12 months, without reversion to MCI or cognitive normal
(NO) at any available follow-up (n = 58); (iii) pMCI late, if diagnosis was MCI at baseline
and conversion to AD was reported after the first 12 months (i.e., at 18, 24, or 36 months
follow-up), without reversion to MCI or NO at any available follow-up (n = 75). Details of the
characteristics of the ADNI test sample are presented in Table 5.1.
To compare the performance of the BrainAGE framework in predicting conversion from
MCI to AD to the commonly used CSF biomarkers A 42, total and phosphorylated tau (T-Tau
and P-Tau), a subsample of subjects with MCI, for whom those CSF data are available, is
utilized (Table 5.1). Adopting the same criteria as described above, this subsample is grouped
as sMCICSF (n = 33), pMCICSF early (n = 32), and pMCICSF late (n = 34). In terms of the
main baseline characteristics (i.e., age, gender, education, cognition, hippocampus volumes), the
CSF subsample was representative of the whole MCI sample used in this study (see Table 5.1).
To train and test the age estimation framework with respect to prediction accuracy and
reliability, we used MRI data of healthy subjects from the publicly accessible IXI cohort (http:
//www.brain-development.org; data downloaded in February 2009) aged 50 years and older.
To evaluate the accuracy of the age estimations, the subjects were divided into training and eval-
uation samples, i.e. after sorting the subjects by age every fourth subject entered the evaluation
sample. Since the number of training samples was found to have the strongest influence on the
accuracy of age prediction, MRI data of healthy subjects from the publicly accessible database
OASIS (http://www.oasis-brains.org; data downloaded in June 2009) aged 50 years and
older were also included in the training sample. In sum the training sample includes 320 cogni-
tive normal elderly subjects. Details of the characteristics of the training sample are presented
in Table 5.2.
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Table 5.1: Baseline characteristics of the MCI samples used in this study.
Whole sample (n = 195) CSF subsample (n = 99) F statistic
pMCI early pMCI late sMCI F statistic pMCICSF early pMCICSF late sMCICSF F statistic (group x
(group) (group) subsample)
No. subjects 58 75 62 - 32 34 33 - -
Males/Females 33/25 48/27 49/13 - 18/14 13/11 27/6 - -
Age range 55–86 56–88 58–88 - 55–86 58–88 63–88 - -
Age mean 73.9 75.2 76.4 1.85 73.4 76.3 76.3 1.88 0.83
(SD) (7.0) (7.3) (6.2) [p = 0.16] (7.0) (7.7) (5.8) [p = 0.16] [p = 0.44]
Education years mean 15.4 16.0 16.5 2.24 15.2 15.7 16.6 1.84 0.29
(SD) (2.9) (2.9) (2.6) [p = 0.11] (3.1) (3.0) (2.4) [p = 0.16] [p = 0.75]
MMSE mean 26.5 26.8 27.7 8.67 26.4 26.6 27.4 2.58 0.46
(SD) (1.9) (1.6) (1.8) [p < 0.001] (2.0) (1.6) (1.8) [p = 0.08] [p = 0.63]
CDR-SB mean 2.0 1.8 1.3 8.97 2.0 1.7 1.3 4.23 0.07
(SD) (0.9) (1.0) (0.7) [p < 0.001] (0.9) (1.1) (0.6) [p < 0.05] [p = 0.93]
ADAS mean 23.5 20.4 16.3 26.60 22.9 20.3 16.5 10.72 0.45
(SD) (6.3) (4.3) (5.8) [p < 0.001] (5.7) (4.4) (6.3) [p < 0.001] [p = 0.63]
Left hippocampus volume mean 2908.7 2923.4 3260.6 9.75 2821.4 2906.9 3273.1 8.09 0.76
(SD) (473.1) (550.9) (478.7) [p < 0.001] (482.0) (516.3) (446.9) [p < 0.001] [p = 0.47]
Right hippocampus volume mean 2950.4 2963.4 3275.6 8.07 2873.5 2877.8 3255.2 7.07 0.29
(SD) (506.1) (550.7) (476.0) [p < 0.001] (446.8) (528.9) (435.8) [p < 0.01] [p = 0.75]
T-Tau mean - - - - 113.8 116.8 99.2 1.11 -
(SD) (54.6) (46.6) (54.1) [p = 0.33]
P-Tau mean - - - - 44.7 39.2 34.9 2.77 -
(SD) (17.1) (15.6) (18.0) [p = 0.07]
A 42 mean - - - - 142.5 147.3 168.5 2.77 -
(SD) (35.7) (38.2) (62.9) [p = 0.07]
[Notes: Bold type = significant test results.]
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Table 5.2: Characteristics of the samples used to model normal brain aging.
Training sample (n = 320) Evaluation sample
IXI OASIS (IXI)
No. subjects 194 126 64
Males/Females 72/122 35/91 24/40
Age mean (SD) 63.5 (7.6) 71.3 (11.8) 63.5 (7.5)
Age range 51–86 51–94 51–83
5.3.2 Preprocessing of MRI data and data reduction
Preprocessing of the T1-weighted images was done using the SPM8 package (http://www.fil.
ion.ucl.ac.uk/spm) and the VBM8 toolbox (http://dbm.neuro.uni-jena.de), running un-
derMatlab. All T1-weighted images were corrected for bias-field inhomogeneities, then spatially
normalized and segmented into grey matter, white matter, and CSF within the same generative
model (Ashburner and Friston, 2005). The segmentation procedure was further extended by
accounting for partial volume e↵ects (Tohka et al., 2004), by applying adaptive maximum a pos-
teriori estimations (Rajapakse et al., 1997), and by using a hidden Markov random field model
(Cuadra et al., 2005) as described previously (Gaser, 2009). Only grey matter (GM) images
were used. Following the pipeline proposed by Franke et al. (2010), the images were processed
with a ne registration and smoothed with 8-mm full-width-at-half-maximum smoothing kernels.
After smoothing, spatial resolution was set to 8 mm. Then, data reduction was performed by ap-
plying principal component analysis (PCA), utilizing the “Matlab Toolbox for Dimensionality
Reduction” (http://ict.ewi.tudelft.nl/⇠lvandermaaten/Home.html). PCA was only performed
on the training sample and the estimated transformation parameters were subsequently applied
to the test sample. No further data reduction or region pre-selection was accomplished.
5.3.3 Relevance vector regression (RVR)
Relevance vector machines (RVM) were introduced by Tipping (2000) as a Bayesian alternative
to support vector machines (SVM) for obtaining sparse solutions to pattern recognition tasks.
The main idea behind SVMs is the transformation of training data from input space into high-
dimensional space – the feature space – via a mapping function   (Bennett and Campbell,
2003; Scho¨lkopf and Smola, 2002). For the purpose of classification, the hyperplane that best
separates the groups is computed within this feature space, resulting in a nonlinear decision
boundary within the input space. The best separating hyperplane is found by maximizing the
margin between the two groups. The data points lying on the margin boundaries are called
support vectors since only these are used to specify the optimal separating hyperplane. For the
case of real-valued output functions (rather than just binary outputs as used in classification), the
SV algorithm was generalized to regression estimation (Bennett and Campbell, 2003; Scho¨lkopf
and Smola, 2002). In support vector regression (SVR), a function has to be found that fits as
many data points as possible. Analogous to the margin in classification, the regression line is
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surrounded by a tube. Data points lying within that tube do not influence the course of the
regression line. Data points lying on the edge or outside that tube are called support vectors.
In contrast to the support vectors in SVM, the relevance vectors in RVM represent the
prototypical examples within the specified classification or regression task, instead of solely
representing separating attributes. Furthermore, severe overfitting associated with the maximum
likelihood estimation of the model parameters was avoided by imposing an explicit zero-mean
Gaussian prior (Ghosh and Mujumdar, 2008; Zheng et al., 2008). This prior is a characteristic
feature of the RVM, and its use results in a vector of independent hyperparameters that reduces
the data set (Faul and Tipping, 2002; Tipping, 2000; Tipping and Faul, 2003). Therefore, in
most cases the number of relevance vectors is much smaller than the number of support vectors.
Furthermore, in SVR additional parameters have to be determined or statistically optimized
(e.g. with cross-validation loops) in order to control for model complexity and model fit. To
control the behavior of the RVR, only the type of kernel has to be chosen, whereas all other
parameters are automatically estimated by the learning procedure itself. More details can be
found in Bishop (2006), Scho¨lkopf and Smola (2002), and Tipping (2000).
5.3.4 Age estimation framework
The BrainAGE framework utilizes RVR (Tipping, 2001) and was recently developed to estimate
individual brain ages based on T1-weighted images (Franke et al., 2010). As suggested by Franke
et al. (2010), the kernel was chosen to be a polynomial of degree 1, since age estimation accuracy
was shown to not improve when choosing non-linear kernels. Thus, parameter optimization
during the training procedure was not necessary.
In general, the model is trained with preprocessed whole brain structural MRI data (as de-
scribed in section 5.3.2) of the training sample. Subsequently, the brain age of a test subject can
be estimated using the individual tissue-classified MRI data, aggregating the complex, multi-
dimensional aging pattern across the whole brain into one single value. The di↵erence between
estimated and true chronological age will reveal the individual “Brain Age Gap Estimation”
(BrainAGE) score. Consequently, the BrainAGE score directly quantifies the amount of accel-
eration or deceleration of brain aging. For example, if a 70 years old individual has a BrainAGE
score of +5 years, this means that this individual shows the typical atrophy pattern of a 75
years old individual. For training the model as well as for predicting individual brain ages, we
used “The Spider” (http://www.kyb.mpg.de/bs/people/spider/main.html), a freely avail-
able toolbox running under Matlab. More detailed information as well as the most important
features data that were used by the RVR for estimating the brain age can be found in Franke
et al. (2010).
Within this study, the framework was separately trained on male and female subjects in the
training sample. With a mean absolute error of 3.8 years in the evaluation sample of healthy
subjects the framework showed accurate performance in brain age estimation. Subsequently, the
brain ages of the test subjects were estimated based on their baseline MRI data. The di↵erence
between the estimated and the true age resulted in the BrainAGE score, indicating accelerated
(positive values) or decelerated (negative values) brain aging. PCA was performed on the training
sample and the estimated transformation parameters were subsequently applied to the test
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subjects.
5.3.5 Statistical analysis
The baseline BrainAGE scores as well as the cognitive scores (i.e. MMSE, CDR-SB, ADAS), the
hippocampus volumes, and the CSF biomarker levels at baseline were compared between the
diagnostic groups in both MCI test samples using an analysis of variance (ANOVA). To assess
the relationship between BrainAGE and cognitive measures at baseline and follow-up, Pearson’s
pairwise correlation was computed.
Receiver operating characteristics (ROC) for discriminating MCI subjects who converted
to AD from those who remained stable during follow-up were computed in both MCI samples,
resulting in the area under the ROC curve (AUC), which is also known as C-statistics or c-index.
The AUC shows the quality of the classification, with 1.0 indicating a perfect discrimination
and 0.5 indicating a result obtained by chance only. In order to test whether the resulting
AUC derived from ROC analysis with BrainAGE is statistically greater than the AUCs of
cognitive scores, hippocampus volumes, and CSF biomarkers, one-tailed z-tests are performed.
Additionally, the McNemar test for paired data was performed in order to statistically test
whether predictions of conversion based on baseline BrainAGE scores are significantly better
than predictions based on cognitive scores, hippocampus volumes, and CSF biomarkers.
Likelihood ratios were computed to determine the likelihood that a BrainAGE score or
biomarker value above a determined threshold would be expected in pMCI relative to sMCI
subjects. These ratios determined whether the use of a clinical biomarker substantially changes
the post-test probability that a subject will convert to AD.
Within both MCI samples, univariate Cox regression was used to estimate the hazard rate
for conversion to AD, adjusting for age, education years, and gender. The time-to-event variable
was time from baseline visit to first visit with AD diagnosis for pMCI subjects. For sMCI sub-
jects, the duration of follow-up was truncated at 3 years. The main predictor was the baseline
BrainAGE score as a continuous variable initially and in quartiles subsequently. For comparison,
Cox regression was also performed with baseline cognitive scores, hippocampus volumes, and
CSF biomarkers as main predictors. As checked by log-minus-log-plots of survival, the assump-
tion of proportional hazards was met for all Cox proportional hazard models. Cox regression
was performed using SPSS. All other statistical testing was performed using Matlab.
5.4 Results
5.4.1 Whole MCI sample
The diagnostic groups (i.e. pMCI early, pMCI late, sMCI) did not di↵er in terms age and edu-
cation years (Table 5.1). As expected, at baseline examination all cognitive scores as well as the
hippocampus volumes di↵ered between groups (Figure 5.1B-F).
The baseline BrainAGE scores significantly di↵ered between the diagnostic groups (F = 26.04,
p < 0.001), resulting in the following means: pMCI early = 8.73 years, pMCI late = 5.62 years,
and sMCI = 0.75 years. As mentioned above, positive values indicate a higher estimated than
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Table 5.3: Results for correlation analyses of baseline BrainAGE scores with cognitive scores at baseline
and follow-up (whole sample).
6 months 12 months 18 months 24 months 36 months
baseline follow-up follow-up follow-up follow-up follow-up
MMSE  0.09  0.17⇤  0.25⇤⇤⇤  0.24⇤⇤  0.39⇤⇤⇤  0.41⇤⇤⇤
CDR-SB 0.20⇤⇤ 0.26⇤⇤⇤ 0.28⇤⇤⇤ 0.32⇤⇤⇤ 0.42⇤⇤⇤ 0.46⇤⇤⇤
ADAS 0.23⇤⇤ 0.24⇤⇤ 0.35⇤⇤⇤ 0.38⇤⇤⇤ 0.44⇤⇤⇤ 0.48⇤⇤⇤
[Notes: ⇤p < 0.05, ⇤⇤p < 0.01, ⇤⇤⇤p < 0.001.]
chronological age. Post hoc t-tests showed significant di↵erences (p < 0.05) between all three
diagnostic groups (Figure 5.1A).
As expected, cognitive abilities substantially declined during the follow-up intervals in both
pMCI groups but remained stable in those who did not convert to AD (Figure 5.2A-C). Sta-
tistically significant correlations at baseline were only found between BrainAGE scores and
CDR-SB as well as ADAS, but not for MMSE (Table 5.3). During follow-up, the correlations
between baseline BrainAGE scores and clinical disease severity as well as cognitive functioning
even increased, denoting a close relationship between pathological brain aging and prospective
worsening of cognitive functioning.
Our test sample included 195 subjects diagnosed with MCI at baseline. During 36 months of
follow-up, a total of 133 of them developed AD, corresponding to a pre-test probability of 68%.
More specifically, 30% of the MCI subjects converted to AD within the first 12 months after
baseline examination (mean time to conversion: 312 ± 96 days), whereas 38% of all MCI subjects
converted to AD after the first year of follow-up (mean time to conversion: 705 ± 228 days). By
varying the threshold applied to the BrainAGE score, we constructed ROC curves for a binary
discrimination between MCI subjects who remained stable during 3 years follow-up from those
who converted to AD. With AUCs (or c-index) of 0.83 and 0.78, and accuracy rates of 81%
and 75% for the discrimination of sMCI vs. pMCI early (Figure 5.3A) and all pMCI subjects
(Figure 5.3B), respectively, the baseline BrainAGE score proved its encouraging potential to
predict conversion to AD in MCI subjects. Furthermore, predicting future conversion to AD
based on baseline BrainAGE scores was significantly more accurate than predictions based on
chronological age, hippocampus volumes, and cognitive scores at baseline (Table 5.4).
For the whole MCI sample the post-test probability was increased to 90% when using baseline
BrainAGE scores to predict conversion to AD within 36 months of follow-up (Figure 5.4A). This
gain in certainty by 22% was highest for the baseline BrainAGE score as compared to baseline
hippocampus volumes (right hippocampus: 16%; left hippocampus: 17%) or cognitive scores
(MMSE: 11%; CDR-SB: 0%; ADAS: 18%).
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Figure 5.1: Baseline scores in all MCI groups. Shown are box plots for baseline (A) BrainAGE
scores (in years), (B) MMSE scores, (C) CDR-SB scores, (D) ADAS scores, (E) left and (F) right hip-
pocampus volumes (in mm3) of all diagnostic groups. Post-hoc t-tests resulting in significant di↵erences
between diagnostic groups are indicated (p < 0.05; red lines). The boxes contain the values between the
25th and 75th percentiles, including the median (gray line). Lines extending above and below each box
symbolize data within 1.5 times the interquartile range (outliers are displayed with a +). Width of the
boxes indicates the group size. [Figure and legend from Gaser et al. 2013.]
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Figure 5.2: Cognitive scores during follow-up.Mean (A) MMSE, (B) CDR-SB, (C) ADAS scores in
pMCI early, pMCI late, and sMCI subjects at baseline examination as well as all follow-up assessments.
Error bars depict the standard error of the mean (SEM). [Figure and legend from Gaser et al. 2013.]
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Figure 5.3: ROC curves of individual subject classification to sMCI or pMCI. ROC curves of
individual subject classification to sMCI or pMCI based on baseline BrainAGE scores, cognitive scores,
and hippocampus volumes for (A) early converters and (B) the whole sample. The areas under the ROC
curves (AUCs) of cognitive scores and hippocampus volumes were tested against the AUC of BrainAGE.
[Notes: ⇤p < 0.05, ⇤⇤p < 0.01, ⇤⇤⇤p < 0.001. Figure and legend from Gaser et al. 2013.]
Figure 5.4: Pre-test and post-test probability for predicting conversion to AD. Pre-test prob-
ability (blue) and post-test probability (blue + red), indicating the gain in prognostic certainty (red) for
predicting conversion to AD within 36 months, based on (A) baseline BrainAGE scores, hippocampus
volume, and cognitive measures within the whole MCI sample, as well as (B) baseline BrainAGE scores
and CSF biomarkers in the CSF subsample. [Figure and legend from Gaser et al. 2013.]
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Table 5.4: Results for predicting conversion to AD in MCI subjects with baseline scores (whole sample).
pMCI early pMCI (all)
Accuracy Sensitivity Specificity McNemar test Accuracy Sensitivity Specificity McNemar test
[CI] [CI] [CI] Error rate
 2
[CI] [CI] [CI] Error rate
 2
[CI] [CI]
BrainAGE score 0.81 0.78 0.84 0.19 - 0.75 0.71 0.84 0.25 -
[0.74–0.88] [0.70–0.85] [0.77–0.90] [0.12–0.26] [0.69–0.81] [0.65–0.78] [0.79–0.89] [0.19–0.31]
Chronological age 0.41 0.29 0.89 0.59 28.69 0.52 0.31 0.85 0.48 15.87
[0.32–0.50] [0.21–0.37] [0.83–0.94] [0.50–0.68] [p < 0.001] [0.45–0.59] [0.24–0.37] [0.80–0.90] [0.41–0.55] [p < 0.001]
MMSE score 0.57 0.71 0.61 0.43 13.07 0.37 0.71 0.61 0.63 50.75
[0.48–0.66] [0.63–0.79] [0.53–0.70] [0.34–0.52] [p < 0.001] [0.31–0.44] [0.64–0.77] [0.54–0.68] [0.56–0.69] [p < 0.001]
CDR-SB score 0.59 0.64 0.77 0.41 15.87 0.38 0.52 0.77 0.62 56.47
[0.50–0.68] [0.55–0.72] [0.70–0.85] [0.32–0.50] [p < 0.001] [0.31–0.45] [0.45–0.59] [0.72–0.83] [0.55–0.69] [p < 0.001]
ADAS score 0.66 0.65 0.81 0.34 5.90 0.48 0.89 0.48 0.52 31.02
[0.57–0.74] [0.56–0.73] [0.74–0.88] [0.26–0.43] [p < 0.05] [0.41–0.55] [0.84–0.93] [0.41–0.55] [0.45–0.59] [p < 0.001]
Left hippocampus volume 0.66 0.52 0.81 0.34 6.42 0.61 0.53 0.81 0.39 8.19
[0.57–0.74] [0.43–0.61] [0.74–0.88] [0.26–0.43] [p < 0.05] [0.54–0.68] [0.46–0.60] [0.75–0.86] [0.32–0.46] [p < 0.01]
Right hippocampus volume 0.61 0.84 0.42 0.39 9.62 0.54 0.43 0.84 0.46 16.00
[0.52–0.70] [0.78–0.91] [0.33–0.51] [0.30–0.48] [p < 0.01] [0.47–0.61] [0.36–0.50] [0.79–0.89] [0.39–0.53] [p < 0.001]
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Cox regression analysis showed an association of higher BrainAGE scores with a higher risk
of developing AD ( 2 = 58.86, p < 0.001; Table 5.5). Each additional year in the BrainAGE score
was associated with a 10% greater risk of developing AD (hazard rate: 1.10, p < 0.001; Table 5.5).
Compared with subjects in the lowest BrainAGE quartile ( 9.55  0.12 years), subjects in the
2nd quartile ( 0.12  4.45 years) had about the same risk of developing AD (hazard ratio [HR]:
1.13 [95% confidence interval (CI): 0.62  2.06], p = 0.68), those in the 3rd quartile (4.46  9.26
years) had a three times greater risk (HR: 3.12 [CI: 1.80 5.40], p < 0.001), and those in the 4th
quartile (9.26 29.20 years) had a four times greater risk (HR: 4.66 [CI: 2.61  8.29], p < 0.001) of
developing AD (Figure 5.5). Thus, MCI subjects showing abnormal atrophy patterns as marked
by higher BrainAGE scores had a significantly increased risk and a cumulative probability of
88% in the 3rd quartile and 92% in the 4th quartile for conversion to AD. Furthermore, when
performing Cox regression with all other baseline scores, BrainAGE again showed the best
results (Table 5.5, Figure 5.6).
Figure 5.5: Cumulative probability of remaining AD-free in the quartiles of baseline
BrainAGE score. Kaplan-Meier survival curves based on Cox regression comparing cumulative AD
incidence in subjects with MCI at baseline by BrainAGE score quartiles (p for trend < 0.001). Duration
of follow-up is truncated at 1250 days. [Figure and legend from Gaser et al. 2013.]
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Figure 5.6: Cumulative probability of remaining AD-free in the whole MCI sample. Kaplan-
Meier survival curves based on Cox regression comparing cumulative AD incidence in subjects with MCI
at baseline by all baseline scores split at median. Duration of follow-up is truncated at 1250 days. [Figure
and legend from Gaser et al. 2013.]
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Table 5.5: Model statistics of Cox regression for all baseline scores (adjusted for age, gender, and education).
Continuous predictors Categorical predictors (median split)
Overall model Continuous values Overall model Values below vs. above median
 2 p
Hazard rate Wald
p  2 p
Hazard ratio Wald
p
[CI] statistics [CI] statistics
BrainAGE score (+) 58.86 ⇤ ⇤ ⇤ 1.10 45.05 ⇤ ⇤ ⇤ 52.23 ⇤ ⇤ ⇤ 3.41 37.03 ⇤ ⇤ ⇤
[1.07–1.13] [2.30–5.07]
MMSE score (–) 28.99 ⇤ ⇤ ⇤ 0.81 16.01 ⇤ ⇤ ⇤ 25.04 ⇤ ⇤ ⇤ 2.02 12.55 ⇤ ⇤ ⇤
[0.73–0.90] [1.37–2.99]
CDR-SB score (+) 30.46 ⇤ ⇤ ⇤ 1.15 19.41 ⇤ ⇤ ⇤ 26.74 ⇤ ⇤ ⇤ 1.97 13.89 ⇤ ⇤ ⇤
[1.26–1.82] [1.38–2.82]
ADAS score (+) 56.02 ⇤ ⇤ ⇤ 1.11 40.48 ⇤ ⇤ ⇤ 29.78 ⇤ ⇤ ⇤ 2.12 16.84 ⇤ ⇤ ⇤
[1.07–1.14] [1.48–3.03]
Left hippocampus volume (–) 34.54 ⇤ ⇤ ⇤ 1.00 21.82 ⇤ ⇤ ⇤ 23.84 ⇤ ⇤ ⇤ 1.91 11.34 ⇤⇤
[1.00–1.00] [1.31–2.78]
Right hippocampus volume (–) 31.65 ⇤ ⇤ ⇤ 1.00 18.90 ⇤ ⇤ ⇤ 18.56 ⇤⇤ 1.59 6.32 ⇤
[1.00–1.00] [1.11–2.28]
[Notes: (+) = higher values mean higher risk for AD, (–) = lower values mean higher risk for AD. ⇤p < 0.05, ⇤⇤p < 0.01, ⇤⇤⇤p < 0.001. Bold type = best performance of all markers.]
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5.4.2 MCI subsample with CSF data
When comparing BrainAGE to state-of-the-art CSF biomarkers within this multicenter study,
only the baseline BrainAGE scores significantly di↵ered between the diagnostic groups in the
CSF subsample (sMCICSF : 0.71 years; pMCICSF late: 5.04; pMCICSF early: 8.20; F = 10.82,
p < 0.001; Figure 5.7), but none of the baseline CSF biomarker levels (Table 5.1). BrainAGE
scores in the CSF subsample did not di↵er between from those in the whole MCI sample
(F = 0.15, p = 0.86).
Figure 5.7: Baseline BrainAGE scores and baseline CSF biomarker concentrations in the
MCI-subsample. Shown are box plots for (A) BrainAGE scores, (B) T-Tau, (C) P-Tau, and (D) A 42
concentration at baseline of all diagnostic groups in the subsample that also provides CSF data. The
boxes contain the values between the 25th and 75th percentiles, including the median (gray line). Lines
extending above and below each box symbolize data within 1.5 times the interquartile range (outliers are
displayed with a +). Width of the boxes indicates the group size. Post-hoc t-tests resulted in significant
di↵erences between diagnostic groups only for baseline BrainAGE scores (p < 0.05; red lines). [Figure and
legend from Gaser et al. 2013.]
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ROC analyses with baseline BrainAGE scores resulted in AUCs (or c-index) of 0.84 and
0.75, and accuracy rates accuracy rates of 80% and 72% for the discrimination of sMCICSF vs.
pMCICSF in early converters (Figure 5.8A) and in the whole CSF subsample (Figure 5.8B), re-
spectively. Thus, baseline BrainAGE scores showed significantly better predictions than baseline
T-Tau, P-Tau, and A 42 levels (Table 5.6).
Furthermore, when looking at the post-test probability in the CSF subsample, the pre-
test probability of 67% for converting to AD within three years was increased by 21% using
baseline BrainAGE scores (Figure 5.4B), but only slightly by using CSF biomarkers (T-Tau:
4%, P-Tau: 0%, A 42: 0%, A 42/P-Tau: 8%).
Also in the CSF subsample, Cox regression analysis showed a significant association of higher
BrainAGE scores with a higher risk of developing AD ( 2 = 22.11, p < 0.001; Table 5.5). In
contrast, Cox regression with CSF biomarkers did not yield significant results for any of them
(Table 5.7, Figure 5.9).
5.5 Discussion
The scope of this study was the implementation of a novel MRI-based biomarker based on the
recently presented BrainAGE framework (Franke et al., 2010) to predict prospective cognitive
decline and conversion to AD on an individual subject level. Using structural MRI data, our fully
automated age estimation model aggregates the complex, multidimensional aging patterns across
the whole brain to one single value (i.e. the BrainAGE score) and finally identifies pathological
brain aging in MCI subjects who finally converted to AD within three years of follow-up, with
increasing BrainAGE scores at baseline indicating an increased risk of developing AD.
Figure 5.8: ROC curves of individual subject classification to sMCI or pMCI in the CSF
subsample. ROC curves of individual subject classification to sMCICSF or pMCICSF based on baseline
BrainAGE scores and CSF biomarkers for (A) early converters and (B) the whole CSF subsample. The
areas under the ROC curves (AUCs) of the CSF biomarkers were tested against the AUC of BrainAGE.
[Notes: ⇤p < 0.05, ⇤⇤p < 0.01. Figure and legend from Gaser et al. 2013.]
C
H
A
P
T
E
R
5.
P
R
E
D
IC
T
IO
N
O
F
C
O
N
V
E
R
S
IO
N
T
O
A
D
U
S
IN
G
B
R
A
IN
A
G
E
85
Table 5.6: Results in the CSF subsample for predicting conversion to AD in MCI subjects with baseline scores.
pMCICSF early pMCICSF (all)
Accuracy Sensitivity Specificity McNemar test Accuracy Sensitivity Specificity McNemar test
[CI] [CI] [CI] Error rate
 2
[CI] [CI] [CI] Error rate
 2
[CI] [CI]
BrainAGE score 0.80 0.91 0.70 0.20 - 0.72 0.67 0.82 0.28 -
[0.70–0.90] [0.83–0.98] [0.58–0.81] [0.10–0.30] [0.63–0.81] [0.57–0.76] [0.74–0.89] [0.19–0.37]
T-Tau score 0.60 0.84 0.39 0.40 4.80 0.58 0.88 0.39 0.42 3.93
[0.48–0.72] [0.76–0.93] [0.27–0.51] [0.28–0.52] [p < 0.05] [0.48–0.76] [0.81–0.94] [0.30–0.49] [0.33–0.52] [p < 0.05]
P-Tau score 0.57 0.78 0.58 0.43 7.54 0.43 0.68 0.58 0.57 16.20
[0.45–0.69] [0.68–0.88] [0.46–0.70] [0.31–0.55] [p < 0.01] [0.34–0.53] [0.59–0.77] [0.48–0.67] [0.47–0.66] [p < 0.001]
A 42 0.57 0.91 0.36 0.43 7.26 0.49 0.89 0.36 0.51 7.08
[0.45–0.69] [0.83–0.98] [0.25–0.48] [0.31–0.55] [p < 0.01] [0.40–0.59] [0.83–0.95] [0.27–0.46] [0.41–0.60] [p < 0.01]
A 42/P-Tau 0.69 0.97 0.42 0.31 1.69 0.73 0.92 0.42 0.27 0.03
[0.58–0.80] [0.93–1.00] [0.30–0.54] [0.20–0.42] [n.s.] [0.64–0.81] [0.87–0.98] [0.33–0.52] [0.18–0.36] [n.s.]
[Notes: n.s. = not significant.]
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Table 5.7: Model statistics of Cox regression for all baseline scores (adjusted for age, gender, and education).
Continuous predictors Categorical predictors (median split)
Overall model Continuous values Overall model Values below vs. above median
 2 p
Hazard rate Wald
p  2 p
Hazard ratio Wald
p
[CI] statistics [CI] statistics
BrainAGE score (+) 22.11 ⇤ ⇤ ⇤ 1.08 14.86 ⇤ ⇤ ⇤ 24.33 ⇤ ⇤ ⇤ 3.41 16.75 ⇤ ⇤ ⇤
[1.04–1.12] [1.89–6.14]
T-Tau (+) 6.90 n.s. 1.00 0.17 n.s. 6.92 n.s. 1.11 0.15 n.s.
[1.00–1.01] [0.67–1.64]
P-Tau (+) 9.54 ⇤ 1.01 2.78 n.s. 7.86 n.s. 1.29 0.96 n.s.
[1.00–1.03] [0.77–2.14]
A 42 (–) 10.33 ⇤ 0.99 3.54 n.s. 6.73 n.s. 0.98 0.00 n.s.
[0.99–1.00] [0.59–1.63]
A 42/P-Tau (–) 12.90 ⇤ 0.91 5.63 ⇤ 6.83 n.s. 1.08 0.10 n.s.
[0.84–0.98] [0.66–1.78]
[Notes: (+) = higher values mean higher risk for AD, (–) = lower values mean higher risk for AD. ⇤p < 0.05, ⇤⇤⇤p < 0.001, n.s. = not significant. Bold type = best performance of all
markers.]
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Figure 5.9: Cumulative probability of remaining AD-free in the CSF subsample. Kaplan-
Meier survival curves based on Cox regression comparing cumulative AD incidence in subjects with MCI
at baseline by all CSF biomarker baseline levels split at median. Duration of follow-up is truncated at
1250 days. [Figure and legend modified from Gaser et al. 2013.]
This method already showed the advantage of accurately and reliably estimating the age
of the brain with minimal preprocessing and parameter optimization (Franke et al., 2010,
2012b), using a single anatomical scan. Regarding the relevance within the clinical context,
higher BrainAGE scores were recently demonstrated to be closely related to measures of clinical
disease severity in AD patients, as well as prospective worsening of cognitive functioning in MCI
subjects who converted to AD within three years (Franke et al., 2012a). Furthermore, already
possessing higher BrainAGE scores at baseline, brain atrophy was shown to even accelerate
during follow-up, with the speed of one additional year per follow-up year in pMCI subjects and
1.5 additional years per follow-up year in AD patients. Considering unequal follow-up durations
in the pMCI and AD groups, this finally accumulated to mean BrainAGE scores of about 9 years
at the last scan in both groups. Compared to that, sMCI and healthy control subjects did not
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show any irregularity in brain atrophy at baseline and follow-up (Franke et al., 2012a).
In the study presented here, the BrainAGE approach was implemented to predict subsequent
conversion to AD on a single subject level based on structural MRI at baseline. Focusing on
subjects with mild memory impairment but preserved activities of daily life, we found accuracy
rates of up to 81% for prediction of progression to AD. Even more interestingly, a high BrainAGE
score increased the prognostic certainty of a subsequent conversion to AD from 68% in our
clinically defined MCI sample to 90%. This gain in certainty may provide solid diagnostic grounds
for early intervention strategies aimed at delaying or preventing the onset of full-scale AD in
subjects at highest risk for the disease. Furthermore, our BrainAGE framework was more precise
in predicting conversion of MCI to AD when compared to chronological age, cognitive scores,
hippocampus volume, or state-of-the-art CSF biomarkers.
Cognitive decline was recently found to progressively accelerate years before being diagnosed
as AD (Wilson et al., 2011), and to be correlated with the atrophy rates in specified brain regions
(Desikan et al., 2008). In addition, some studies focusing on regression methods to identify
pathological brain structures specific for AD reported moderate performance measures when
predicting one-year decline of cognitive functions in MCI (Duchesne et al., 2009; Stonnington
et al., 2010; Wang et al., 2010). Although not specifically trained to predict changes in cognitive
scales, the BrainAGE scores estimated at baseline showed moderate correlations with measures
of clinical disease severity and cognitive functioning up to three years in advance. These results
as well as our recent results from a longitudinal BrainAGE study (Franke et al., 2012b) support
the suggested relationship between progressive acceleration in brain atrophy and worsening of
cognitive functioning in progressive MCI.
Using high-dimensional pattern recognition with imaging data was recently suggested to
provide a viable biomarker to detect subtle, but predictive, imaging phenotypes that precede
cognitive decline while there is still opportunity for preventive or therapeutic interventions (Clark
et al., 2012). Current classification approaches attempt to identify disease-specific patterns that
allow a separation of subjects with MCI or AD from healthy samples. Whilst most approaches
are able to accurately di↵erentiate between healthy controls and AD patients (Hinrichs et al.,
2011; Walhovd et al., 2010; Zhang et al., 2011), it is the conversion from MCI to AD that
is of greater clinical interest and clinical consequence. Attempting this issue, most approaches
showed a substantial drop in accuracy when predicting MCI-to-AD conversion on an individual
level, especially when relying on baseline data only (Davatzikos et al., 2011; Misra et al., 2009;
Querbes et al., 2009; Teipel et al., 2007; Vemuri et al., 2009b; Westman et al., 2011). Nevertheless,
individuals showing the first subtle signs of abnormal atrophy will benefit most from an early
therapy, provided to reliably identify those individuals at risk of progressing to AD in future. For
example, a recent study based on cortical thickness reported the accurate detection of 81% of
those MCI subjects who were to be clinically diagnosed as AD patients 24 months later (Querbes
et al., 2009). But this was only true when looking at those MCI subjects who were converting to
AD, while ignoring those MCI subjects who did not convert. Consequently, the overall accuracy
of sMCI vs. pMCI classification ranged from 48% at 6 months to 73% at 24 months. Furthermore,
although a very recent study reported that combining MRI and CSF measures in a multivariate
model resulted in better accuracy for predicting future conversion from MCI to AD, than using
CHAPTER 5. PREDICTION OF CONVERSION TO AD USING BRAINAGE 89
either MRI or CSF separately (Westman et al., 2012), the overall prediction accuracies for
converters and non-converters ranged only from 58.6% to 66.4% at di↵erent time points. With
sensitivity of 67% and specificity of 69%, another recent study (Wolz et al., 2011) also achieved
the most stable and reliable classification results when combining all available structural MRI
features (i.e., hippocampus volume, tensor-based morphometry, cortical thickness). Thus, with
accuracy rates up to 81% in predicting conversion to AD within the whole MCI sample up
to three years in advance, BrainAGE is comparable or even outperforms recent classification
studies that predicted decline of cognitive scores in MCI subjects or short-term conversion to
AD (e.g., Davatzikos et al., 2011; Fan et al., 2008a; Misra et al., 2009; Querbes et al., 2009;
Teipel et al., 2007; Westman et al., 2011).
Besides and in contrast to CSF biomarkers, MRI is non-invasive and can be performed more
rapidly than a detailed neuropsychological testing. Furthermore, brain imaging is part of the
diagnostic work-up (Walhovd et al., 2010), with MRI becoming the imaging modality of choice
in many centers. Additionally, MRI was shown to retain the closest relationship with memory
loss as well as worsening of clinical functions (Jack et al., 2010). Consequently, current models
of the dynamics of well established biomarkers of the Alzheimer’s pathological cascade suggest
a crucial role for structural MRI in predicting future cognitive decline and conversion to AD
(Clark et al., 2012; Frisoni et al., 2010; Jack et al., 2010). Even though hippocampus volume has
been shown to represent an independent risk factor for AD and robustly predicting conversion
to AD in MCI subjects, the BrainAGE approach outperformed prediction utilizing baseline
hippocampus volumes in the present study as well as in recently published classification studies
(Costafreda et al., 2011; Risacher et al., 2009, 2010).
One limitation of our approach might be that white matter lesions that occur primarily
due to cerebro-vascular diseases are not detected in the segmentation approach. Those lesions
are segmented as gray matter and might therefore influence the relevance vector regression.
However, because such lesions only occur in a limited number of subjects it is very unlikely
that they contribute to the relevance vectors because of their high local variance. In future,
the segmentation should be extended by methods that allow an automated detection of white
matter lesions even without any additional FLAIR sequence (Klo¨ppel et al., 2011).
As stated before, the BrainAGE method builds on the assumption of AD being preceded by
an acceleration in brain atrophy that resembles advanced aging (e.g., Cao et al., 2010; Driscoll
et al., 2009; Dukart et al., 2011; Jones et al., 2011; Saetre et al., 2011; Spulber et al., 2010), al-
though there are other studies rejecting that assumption (e.g., Nelson et al., 2011; Ohnishi et al.,
2001). However, the acceleration of spatiotemporal brain atrophy might only be seen in subjects
in a preclinical stage, while in AD patients additional disease-specific pathological changes are
occurring. Further, subjects with a high BrainAGE score but no AD-specific clinical profile may
su↵er from other neurodegenerative diseases. This issue should be explored by applying our
framework to other neurodegenerative diseases. Furthermore, cognitive reserve, genetic status,
education level, socioeconomic status, lifestyle, or vitamin supply may protect subjects from
pathological brain aging or accelerated cognitive decline despite high BrainAGE scores (Chen
et al., 2009; Fotenos et al., 2008; Mangialasche et al., 2013; Querbes et al., 2009; Snowdon,
2003). Thus, in future research we aim to disentangle age- and unrelated disease-based processes
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of brain tissue loss in AD. Additionally, we will elucidate the e↵ects of the genetic status, e.g.,
Apolipoprotein E (APOE), on the longitudinal changes in BrainAGE as well as on prediction of
AD conversion, since especially the APOE "4 allele is associated with modification of cognitive
functioning (Cosentino et al., 2008; Deary et al., 2002; Wishart et al., 2006) and GM reduction
in AD patients (Filippini et al., 2009) as well as healthy subjects (Bookheimer et al., 2000).
In conclusion, BrainAGE has shown promising results on an individual level, contributing
to an early indication of pathological brain aging in advance of severe clinical symptoms, or
even predicting future cognitive decline. Compared to a wide range of existing classification
approaches that require disease-specific data for training, the BrainAGE framework uses an
independent database of healthy, non-demented subjects to model the normal brain-aging pat-
tern and consequently recognizing subtle deviations from age-related brain atrophy in new test
samples. As the BrainAGE approach utilizes only a single T1-weighted image per subject and
already has proven to work fast and fully automated with multi-centre data, it can be eas-
ily implemented in clinical routine to encourage the identification of subtly abnormal atrophy
patterns.
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Chapter 6
General Discussion
The general scope of this work was the development and implementation of a novel biomarker
that aggregates the complex, multidimensional aging pattern across the whole brain into one
single value; i.e. the BrainAGE score. Using structural MRI data, the BrainAGE score directly
quantifies acceleration or deceleration in individual brain aging, thus providing clinically relevant
information about normal or even abnormal age-related changes in the brain structure. In order
to facilitate usability in a clinical routine, the algorithm should work fast and be fully automatic.
The BrainAGE approach estimates the neuroanatomical brain age with minimal preprocessing
and parameter optimization, using a single structural MRI scan.
6.1 Stability of BrainAGE estimation
The proposed BrainAGE approach comprises well established and fully automated processing
of structural MR images to aggregate the complex, region-specific, and non-linear patterns of
neurodegenerative age-related changes across the whole brain into one single value, thus provid-
ing a reference curve for healthy brain aging. The algorithm makes use of the whole pattern in
the brain image and additionally takes inter-regional dependencies into account (Bishop, 2006;
Scho¨lkopf and Smola, 2002). It further allows combining data from di↵erent MR scanners.
With an overall mean absolute (MAE) error of only 5 years and a correlation of r = 0.92
between chronological age and estimated brain age in a sample of 650 healthy subjects aged
between 20 and 86 years (see chapter 2), this age estimating framework turned out to be a
straightforward method to accurately and reliably estimate age with minimal preprocessing and
parameter optimization. Additionally, in a recent study with a sample of about 400 healthy
children and adolescents, aged 5 – 18 years, the BrainAGE framework performed even better,
resulting in a MAE of only 1 year and a maturation curve that accounted for 87% sample variance
(Franke et al., 2012b). Most remarkably, although brain maturation in childhood as well as brain
aging in late life comprise very complex, multidimensional, and highly variable processes (Good
et al., 2001; Lebel and Beaulieu, 2011; Lenroot and Giedd, 2006; Raz and Rodrigue, 2006; Resnick
et al., 2003; Wilke and Holland, 2003), the confidence intervals of estimated brain age did not
change as a function of age during brain maturation (Franke et al., 2012b) and brain aging (see
chapter 2), underlining the potential of the approach to correctly capture the multidimensional
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characteristics of the di↵erent maturational and aging processes occurring in childhood and old
age, respectively.
The amount of explained variance between chronological and estimated or predicted brain age
as achieved by the presented BrainAGE approach was at least comparable or even better than by
other approaches which provided a reverence curve for age-related brain changes using structural
(Ashburner, 2007; Brown et al., 2012; Lao et al., 2004; Neeb et al., 2006) or functional (Dosenbach
et al., 2010) MRI data. This holds true even though much less preprocessing and parameter
optimization was used as compared to recent approaches (Brown et al., 2012; Dosenbach et al.,
2010). Although it is conceivable that the combination of diverse data modalities (e.g., structural,
functional, DTI) might achieve even higher prediction accuracies, the required multidimensional
dataset would constitute a clear drawback. Additionally, structural imaging – in contrast to
functional MRI – avoids potential biases due to diverse confounding influences (e.g., alertness,
vigilance; Van Dijk et al., 2012) and already is the imaging modality of choice in most centers.
Also, when using the BrainAGE method, multidimensional data appear to be not necessarily
needed. Even more interesting, neither of the aforementioned approaches demonstrated the
potential to provide diagnostic information in clinical samples.
Several variables were found to have the potential to influence the accuracy of age prediction,
such as the number of subjects in the training sample, various parameters in data acquisition
(e.g., field strength, scanning sequence) and data preprocessing (e.g., registration, smoothing),
as well as the chosen approach to reduce data dimensionality (e.g., PCA; see chapters 2 and 3).
Consequently, these variables need to be carefully controlled for in future studies. Even though,
with intraclass correlations (ICC) up to 0.93 between the BrainAGE scores calculated from
two shortly delayed scans and even across di↵erent MRI scanners, the BrainAGE framework
proved its ability to provide very stable and reliable estimates (see chapter 3). Although sample-
specific o↵sets in BrainAGE estimation sometimes emerge due to diverse parameters (e.g., kind
of MRI scanner, field-strength, scanning sequences), those o↵sets can be easily corrected for by a
linear shift, as they were systematic across subjects within the same sample. Consequently, when
comparing BrainAGE scores in di↵erent clinical samples, a sample of healthy subjects should
be included in order to control for a potential o↵set. On the other hand, if only di↵erences in
BrainAGE between two subsamples of the same sample or correlations to other measures are
examined, there is no urgent need for the inclusion of control subjects and sample-specific o↵set
correction.
When establishing a clinically valuable reference curve for structural age-related brain changes,
an additional challenge is to develop an algorithm that allows combining data from di↵erent MRI
scanners. The BrainAGE framework demonstrated strong stability of the estimated brain age,
even with entirely new data that di↵ered from the training data – not only by scanner but also by
scanning parameters. Importantly, applying the BrainAGE method to data from scanners that
were not included in the training step, the results proved to be reliable and moreover clinically
valuable (see chapters 2 and 3; see also Franke et al., 2012b). Thus, with respect to combin-
ing data from di↵erent scanners and controlling for potential o↵sets, the BrainAGE framework
proved to perform accurately, robustly, and even scanner-independently. These encouraging re-
sults are in line with (Klo¨ppel et al., 2008b), indicating that the e↵ect of scanner parameters is
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su ciently di↵erent from that of the aging process, and that the BrainAGE method generalizes
well across di↵erent scanners.
6.1.1 Limitations of the BrainAGE approach
It should be noted, that the BrainAGE approach was implemented to model a reference curve
for “normal” structural brain maturation (Franke et al., 2012b) or brain aging (see chapter
2). Therefore, and in this stage of model development, the application to clinical samples is
only recommended if the underlying disease is likely to result from overall deceleration or ac-
celeration of brain maturation or brain aging, such as observed in subjects with developmental
delays (Harbord et al., 1990; McLaughlin et al., 2010; Ramenghi et al., 2011; Verbruggen et al.,
2009), schizophrenia (Kirkpatrick et al., 2008; Thompson et al., 2004), or Alzheimer’s Disease
(Bartzokis, 2011; Cao et al., 2010; Driscoll et al., 2009; Dukart et al., 2011; Jones et al., 2011;
Saetre et al., 2011; Spulber et al., 2010; Thompson et al., 2004). Future work will extend and
refine the current approach to allow identifying significant regional deviations from the expected
age-specific pattern in order to provide region-specific information as a basis for further clinical
applications.
Since diverse parameters were found to have the potential to influence the accuracy of age
prediction (see chapters 2 and 3), the impact of varying image quality and segmentation quality in
training and test data on brain age estimation quality could limit the reliability of the proposed
method and thus should be carefully controlled in future studies. Additionally, they will be
further analyzed within even larger samples.
One limitation of the BrainAGE approach might be that white matter lesions, which oc-
cur primarily due to cerebro-vascular diseases, are not detected in the segmentation approach.
Those lesions are segmented as gray matter and might therefore influence the relevance vector
regression. However, because such lesions only occur in a limited number of healthy subjects,
whose data are used to build the reference curve for healthy brain aging, it is very unlikely
that they contribute to the relevance vectors because of their high local variance. In future, the
segmentation should be extended by methods that allow to detect white matter lesions even
without any additional FLAIR sequence (Schwarz et al., 2009).
Several factors like cognitive reserve, education level, or socioeconomic status may protect
subjects with anatomical signs of accelerated brain atrophy from developing AD and showing
declining test performance, or could at least delay this process (Fotenos et al., 2008; Querbes
et al., 2009; Snowdon, 2003). Consequently, subjects with high BrainAGE scores may not show
AD-specific clinical symptoms yet, even though accelerated brain atrophy is already detectable
at MRI. Future research will further investigate the relationship between cognitive reserve and
BrainAGE.
Additionally, subjects with a high BrainAGE score but no AD-specific clinical profile may
su↵er from other neurodegenerative diseases. Depending on the availability of data, this issue
should be explored by applying the BrainAGE method to other neurodegenerative diseases, i.e.
predicting the severity of symptoms or the possible rate of decline of relevant clinical measures.
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6.2 Application of the BrainAGE approach to clinical samples
As stated before, AD is widely believed to be a form of, or at least associated with, accelerated
aging (Cao et al., 2010; Driscoll et al., 2009; Jones et al., 2011; Saetre et al., 2011; Spulber et al.,
2010; Thompson et al., 2004), with subtle structural brain changes accumulating over many years
and dementia being the final stage (Frisoni et al., 2010; Jack et al., 2010). These processes may
be caused by precocious and/or more pronounced myelin breakdown that leads to precocious
an/or accelerated tissue loss, finally manifesting in severe disease pathology (Bartzokis, 2004,
2011; Bartzokis et al., 2012; Lu et al., 2011, 2013). In line with that, atrophied regions detected
in AD patients were found to largely overlap with regions a↵ected by “normal” age-related
atrophy (Dukart et al., 2011).
The BrainAGE approach repeatedly proved its potential to indicate abnormal age-related
neuroanatomical changes based on structural MRI data. Subjects with AD as well as MCI
subjects who cognitively declined and converted to AD (i.e. pMCI) exhibited significantly larger
baseline BrainAGE scores compared to control subjects as well as those with MCI who remained
cognitively stable (i.e. sMCI; see chapters 3 and 5). Furthermore, the BrainAGE framework even
proved its capability to recognize accelerated brain atrophy in a longitudinal design. Already
starting with a significantly higher baseline BrainAGE score in pMCI and AD, age-related
brain atrophy were shown to accelerate even more during follow-up. Compared to that, sMCI
and healthy control subjects did not show any deviations from healthy brain aging at baseline or
at follow-up. These results are in line with recent studies that showed increased GM atrophy in
AD (Anderson et al., 2012), accelerated changes in whole brain volume in MCI (Driscoll et al.,
2009), acceleration in atrophy rates as subjects progress from MCI to AD (Jack et al., 2008), and
greater GM loss in certain regions in pMCI subjects (Che´telat et al., 2005; Desikan et al., 2008;
Leow et al., 2009; McDonald et al., 2012; Sluimer et al., 2009). Additionally, the results further
support the assumption of AD being a form of or at least being associated with accelerated
age-related brain changes (Bartzokis, 2011; Cao et al., 2010; Driscoll et al., 2009; Dukart et al.,
2011; Jones et al., 2011; Saetre et al., 2011; Spulber et al., 2010; Thompson et al., 2004).
Even more interesting, acceleration in brain aging was found to already be increased by about
4.5 years in T2DM subjects as compared to non-diabetic controls (see chapter 4). Furthermore,
the BrainAGE scores additionally increased in T2DM patients, but not in controls, during
follow-up. This is in line with recent results, suggesting that T2DM leads to structural brain
changes that show the pattern of accelerated aging (Araki et al., 1994; Biessels et al., 2006;
Gispen and Biessels, 2000; Tan et al., 2011; van Elderen et al., 2010; Velayudhan et al., 2010),
as well as further extends the body of evidence suggesting that acceleration in brain aging in
T2DM is already quantifiable in a preclinical stage. Hence, the observed acceleration of brain
atrophy in T2DM is likely to be associated with a precocious Alzheimerization (Bartzokis, 2011)
and thus may reduce the threshold for developing dementia (Biessels et al., 2006).
Moreover, within this whole sample, those subjects with higher BrainAGE scores were more
likely to consume more alcohol, which is in line with recent studies that claimed a U-shaped re-
lationship between alcohol consumption and cognitive impairment (Anttila et al., 2004; Solfrizzi
et al., 2008). Fasting blood glucose levels as a potential indicator of hyperglycemia, were also
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positively related to BrainAGE scores even in non-diabetic adults, supporting the notion about
glucose-mediated accelerated brain aging in T2DM and even in the prediabetic state (Biessels
et al., 2006; Tan et al., 2011). Even more interesting, increased TNF↵ levels, which were recently
found to have a central role in the pathogenesis of AD (Tobinick and Gross, 2008), were also
strongly related to higher BrainAGE scores. Consequently, future research will further explore
the influences of health and lifestyle markers (e.g., metabolic syndrome, hypertension, nicotine
and alcohol abuse, tHcy levels, vitamin B12 levels) on brain aging in cognitively non-impaired
samples.
6.2.1 Associations of BrainAGE with cognitive functions
Although not specifically trained to predict changes in cognitive scales, individual BrainAGE
scores were profoundly associated with measures of cognitive functioning as well as clinical
disease severity in pMCI subjects and AD patients and even to its prospective worsening (see
chapters 3 and 5). These results support the recently suggested relationship between progressive
acceleration in brain aging and rate of cognitive decline as well as clinical disease severity in
pMCI and AD samples (Desikan et al., 2008; Wilson et al., 2011).
Even more interesting, in pMCI subjects, accelerated brain aging was shown to be more
closely related to the worsening of higher cognitive functions, whereas in AD patients, accelerated
brain aging was more closely related to disease severity. However, the BrainAGE scores in
healthy controls and sMCI subjects did not show significant correlations to measures cognitive
functioning and disease severity. This may be mainly due to the fact that the scales analyzed in
these studies were used specifically to identify clinical decline and deterioration in basic cognitive
functioning in clinical samples. Consequently, future work will further explore the relationship
between BrainAGE and higher cognitive functions, applying cognitive scales that are more
appropriate to capture healthy cognitive aging.
Even in T2DM subjects without cognitive impairment, those with higher BrainAGE scores
showed worse verbal fluency (see chapter 4). These results are consistent with previous findings
that suggest subclinical cognitive impairment in T2DM and even in the prediabetic state (Baker
et al., 2011; Tan et al., 2011; van Elderen et al., 2010). Finally, subjects with higher BrainAGE
scores were also more likely to be depressed, which is line with recent studies that linked de-
pression to a state of accelerated aging (Heuser, 2002; Wolkowitz et al., 2010, 2011) as well as
showed an increased risk of dementia in patients with depression in general, and even worse in
T2DM patients (Katon et al., 2012).
6.2.2 Prediction of prospective conversion to AD using BrainAGE
Predicting prospective worsening of cognitive functions and ultimiately conversion to AD using
the novel BrainAGE approach builds on the assumption that AD is preceded by an acceleration
in brain atrophy, which resembles the structural brain changes seen in healthy brain aging, and
thus is already quantifiable in a preclinical stage (e.g., Bartzokis, 2011; Cao et al., 2010; Driscoll
et al., 2009; Dukart et al., 2011; Jones et al., 2011; Saetre et al., 2011; Spulber et al., 2010;
Thompson et al., 2004). Consequently, the detection and quantification of abnormal (brain)
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changes is important for the prospective identification and subsequent treatment of individuals
at risk for cognitive decline and dementia.
Although the best validated biomarkers for an early detection of AD include markers of brain
 -amyloid-plaque deposition (e.g., decreased CSF A 42) as well as markers of neurodegeneration
(e.g., increased CSF tau, decreased fluorodeoxyglucose uptake on PET (FDG-PET), and struc-
tural MRI measures of cerebral atrophy; Bartzokis, 2011; Jack et al., 2010), MRI was found to
retain the closest relationship with cognitive decline (Jack et al., 2010; Vemuri et al., 2009a,b),
suggesting a crucial role for structural MRI in predicting future conversion to AD (Frisoni et al.,
2010; Jack et al., 2010). A recent longitudinal study provides additional support by reporting
that those changes in brain structure occur several years before decline in cognitive functioning
is measurable (Clark et al., 2012). Thus, the acceleration of spatiotemporal brain atrophy might
only be seen in subjects in a preclinical stage, while in AD patients additional disease-specific
pathological changes are occurring. In future research those age- and unrelated disease-based
processes of brain tissue loss in AD should be disentangled.
Using high-dimensional pattern recognition with imaging data was recently suggested to
provide a viable biomarker to detect subtle, but predictive, imaging phenotypes that precede
cognitive decline while there is still opportunity for preventive or therapeutic interventions (Clark
et al., 2012). Current classification approaches attempt to identify disease-specific patterns that
allow a separation of subjects with MCI or AD from healthy samples. Whilst most approaches
are able to accurately di↵erentiate between healthy controls and AD patients (Hinrichs et al.,
2011; Walhovd et al., 2010; Zhang et al., 2011), it is the conversion from MCI to AD that is
of greater clinical interest and consequence, since individuals showing the first subtle signs of
abnormal atrophy will benefit most from an early therapy.
In contrast to all existing approaches, the BrainAGE model aggregates the complex, multi-
dimensional aging patterns across the whole brain and finally identifies abnormal brain atrophy
in pMCI subjects prior to final conversion to AD, with increasing BrainAGE scores indicating
an increased risk of developing AD. With accuracy rates up to 84% in predicting conversion
to AD on an individual level up to three years in advance based on baseline MRI only (see
chapter 5), the BrainAGE approach is in line with or even outperforms recent classification
studies that predicted decline of cognitive scores in MCI subjects or short-term conversion to
AD (Davatzikos et al., 2011; Fan et al., 2008a; Misra et al., 2009; Querbes et al., 2009; Teipel
et al., 2007; Westman et al., 2011). Even more interestingly, a high BrainAGE score increased
the prognostic certainty of a subsequent conversion to AD from 68% in the clinically defined
MCI sample to 90%. This gain in certainty may provide solid diagnostic grounds for early in-
tervention strategies aimed at delaying or preventing the onset of full-scale AD in subjects at
highest risk for the disease.
Furthermore, the BrainAGE framework proved to be more precise in predicting conversion
of MCI to AD when compared to chronological age, cognitive scores, hippocampus volume, or
state-of-the-art CSF biomarkers. Although recent studies reported that combining MRI and CSF
measures in a multivariate model resulted in better accuracy for predicting future conversion
from MCI to AD than using either MRI or CSF separately (Westman et al., 2011), the BrainAGE
approach, using only whole-brain structural baseline MRI, substantially improved classification
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accuracy and predictive power in detecting early AD. In contrast to CSF biomarkers, MRI is
non-invasive and can be performed more rapidly than a detailed neuropsychological testing.
Additionally, current models of the dynamics of well established biomarkers of the Alzheimer’s
pathological cascade suggest a crucial role for structural MRI in predicting future cognitive
decline and conversion to AD, as MRI was shown to retain the closest relationship with memory
loss as well as worsening of clinical functions (Clark et al., 2012; Frisoni et al., 2010; Jack et al.,
2010). Even though hippocampus volume has been shown to represent an independent risk
factor for AD and robustly predict conversion to AD in MCI subjects, the BrainAGE approach
substantially outperformed prediction utilizing baseline hippocampus volumes within this study
as well as recently published classification studies (Costafreda et al., 2011; Risacher et al., 2009,
2010).

Chapter 7
Conclusions and perspectives
To summarize, the BrainAGE approach demonstrated its potential to provide a reliable, clini-
cally sensitive, as well as easy-to-use reference curve of healthy brain aging. It was also repeatedly
shown that this method can be applied to data from di↵erent scanners, which is an important
prerequisite for use in clinical routines. Furthermore, the BrainAGE method has shown promis-
ing results on an individual level, contributing to an early indication of AD in advance of clinical
symptoms, and even predicting prospective decline of clinical measures, thus probably facilitat-
ing early treatment or preventative interventions. Depending on data availability, future research
could include application of the the BrainAGE framework in order to evaluate therapeutic ef-
fects of drugs or other treatment modalities. Since diverse health and lifestyle factors were found
to contribute to the risk of cognitive decline and even developing dementia, future explorations
will apply the BrainAGE approach to subjects with the metabolic syndrome (Solfrizzi et al.,
2011), or other lifestyle factors (Chen et al., 2009; Clarke, 2006; Scarmeas et al., 2009; Sol-
frizzi et al., 2008), to predict the severity of clinical symptoms or the rate of cognitive decline.
Furthermore, the relationship between the duration of exposure to risk factors and accelerated
brain aging, and whether reversal of modifiable factors might decelerate the progression of brain
aging, should be investigated.
Additionally, the BrainAGE framework avoids time-consuming processing steps like man-
ual segmentation and has already proven its ability to be e ciently used and to yield stable
performance with multicenter studies as well as new test samples, unseen within the model
training procedure. Furthermore, to train the BrainAGE algorithm for modeling the normal
aging pattern, only a database of healthy, non-demented subjects is necessary. This is a unique,
distinguishing feature compared to existing approaches that also need data of MCI and/or AD
patients to predict cognitive decline or future conversion to AD.
Given that the BrainAGE framework is validated as well as fast and easy to use, this method
holds great potential for application in daily clinical routine, especially since brain imaging has
become part of the standard diagnostic work-up for many neuropsychiatric and neurodegenera-
tive disorders.
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